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ABSTRACT 
 
DEVELOPING MODELS TO INVESTIGATE MECHANISMS OF GENOMIC IMPRINTING 
Stellar K. Hur 
Dr. Marisa S. Bartolomei 
Genomic imprinting is a conserved, essential process in mammalian 
development that regulates the expression of a small number of genes in a monoallelic, 
parent-or-origin-specific manner. Misregulation of imprinted genes is associated with 
imprinting disorders including Beckwith-Wiedemann syndrome (BWS) and Silver-Russell 
syndrome (SRS) that exhibit abnormal growth phenotypes. These disorders are 
associated with aberrant regulation of the imprinted loci in human 11p15 including the 
H19/IGF2 locus. Finding various alterations of 11p15 associated with BWS and SRS 
inspires investigation of imprinting mechanisms in human, which could provide insights 
into therapeutics. Mouse models have been fundamental to the study of mechanisms of 
imprinting, serving as a proxy for the orthologous human locus. However, elements that 
regulate genomic imprinting, the imprinting control regions (ICRs), often diverge across 
species. Thus, it is essential to first understand whether the diverged ICR has a species-
specific role in regulating imprinting. In Chapter 2, we generated a mouse in which the 
human ICR sequence replaces the orthologous mouse ICR at the H19/Igf2 locus. We 
show that the imprinting mechanism has partially diverged between mouse and human, 
depending on the parental origin of the human ICR sequence in mouse. Additionally, we 
find that this mouse model is optimal for studying specific alterations associated with 
BWS and SRS. The partially diverging imprinting mechanism between mouse and 
human suggests that entirely human models are compelling alternatives. In Chapter 3, 
we demonstrate the derivation of induced pluripotent stem cells (iPSCs) from BWS 
patient fibroblasts. We find that the iPSCs exhibit proper epigenetic and transcriptional 
vi 
 
signatures of BWS. Although we find that certain aspect of epigenetic perturbation is 
inevitable in our iPSCs, the consequence of this perturbation remains unknown. 
Therefore, we propose that the iPSCs can be differentiated into clinically-relevant cell 
types to elucidate molecular mechanisms leading to BWS. Overall, the work in this 
dissertation underscores the versatile and complementary use of different model 
systems in investigating imprinting mechanisms. In addition to serving as platforms to 
model imprinting disorders, these models provide insights into the evolutionary 
perspective of imprinting as well as the significance of various epigenetic mechanisms 
that regulate imprinting.  
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1.1 Genomic imprinting 
Two copies of autosomal genes exist in the mammalian genome, with each copy 
inherited from the respective parental allele. The majority of mammalian genes are 
simultaneously expressed or silenced from both parental alleles. However, a subset of 
genes, known as imprinted genes, are uniquely regulated such that their expression 
occurs in a monoallelic, parent-of-origin-specific manner (Figure 1.1).  
Although imprinted genes comprise a small portion of the genome—about 150 
imprinted genes have been identified in mouse and around half of them are conserved in 
human—they are essential for normal embryonic development (Moore et al., 2015; 
Plasschaert and Bartolomei, 2014). In 1984, androgenetic (two paternal pronuclei) and 
gynogenetic (two maternal pronuclei) mouse embryos were generated by transplanting 
pronuclei between one-cell-stage embryos. Here, uniparentally-derived embryos failed to 
complete normal embryogenesis (Barton et al., 1984; McGrath and Solter, 1984). These 
classic studies suggested that gene expression differences must exist between the 
maternally and paternally inherited chromosomes and that normal development requires 
both maternally and paternally expressed genes. Imprinted genes were unknown at the 
time. However, subsequent studies in mouse models identified imprinted genes (for the 
list of mouse imprinted genes see, http://www.mousebook.org/mousebook-
catalogs/imprinting-resource) and illustrated that disruption of gene dosage or regulation 
of these genes could severely impair embryonic growth, explaining the phenomena 
observed in the androgenetic and gynogenetic embryos. Various human imprinting 
disorders have also been described, with individuals displaying growth, neurological, and 
metabolic clinical features (Kalish et al., 2014; Peters, 2014; Plasschaert and Bartolomei, 
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2014). This emphasizes the conserved importance of correct regulation and expression 
of imprinted genes for proper mammalian development.  
1.1.1 Hypotheses on origins of genomic imprinting 
Imprinted genes are conserved in mammals, and they have significantly 
expanded in the therian lineage of mammals such as marsupials and eutherians 
(placental mammals) (Renfree et al., 2013). Due to their complex nature of parental 
allele-specific regulation and subsequent monoallelic expression, imprinted genes are 
especially susceptible to various genetic/epigenetic challenges. Why, then, would 
mammals develop such a costly mechanism of gene expression that could make the 
organism more vulnerable to insults? To start addressing this question, it is worth 
reviewing the two widely accepted hypotheses on the evolution of genomic imprinting.  
The parental-conflict theory proposes that each parental genome has conflicting 
“interests” in provisioning offspring. For example, paternally expressed genes prefer to 
promote the growth of embryos to increase their genetic fitness. On the other hand, 
maternally expressed genes try to suppress growth of embryos, allowing for more equal 
allocation of limited maternal reproductive resources across successive pregnancies. In 
support of this hypothesis, many paternally expressed imprinted genes such as Igf2, 
Kcnq1ot1, Dlk1, Rasgrf1, Peg1, Peg3, Peg10, Rtl1, and Plagl1 promote growth, and the 
maternally expressed imprinted genes, such as H19, Cdkn1c, Phlda2, Igf2r, and Grb10 
suppress growth (Patten et al., 2014; Renfree et al., 2013).      
Another hypothesis known as the maternal-offspring coadaptation theory 
proposes that genomic imprinting has evolved in the context of coordinating the 
maternal-offspring interactions to increase the fitness of offspring. The theory posits that 
monoallelic (compared to biallelic) expression of genes allows for a more rapid 
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adaptation of important traits for provisioning offspring, such as embryonic growth and 
maternal care. For example, the paternally expressed Peg3 gene is important not only 
for proper maternal care and growth of the placenta by adult females, but also for 
regulating ability of neonates to suckle (Isles, 2009; Renfree et al., 2013). Thus, this 
gene might have evolved to be critical for facilitating the interaction between mom and 
offspring, leading to imprinted, and thus fine-tuned expression. This hypothesis is further 
supported by the fact that the majority of imprinted genes are expressed in placenta, a 
vital tissue that connects physiology between mom and fetus (Renfree et al., 2013).   
Each theory proposes a slightly distinct view on the origins of imprinting. 
However, both theories share a common theme: imprinting must have evolved to 
facilitate coordination and/or adaption of expression of a subset of genes in response to 
the demands of complex biological processes required during mammalian development. 
These intriguing theories underscore the need to further probe the evolutionary 
perspective of imprinted genes at a molecular level. To this end, systematic investigation 
on functions and mechanisms of imprinted genes in various mammalian species will be 
valuable.  
1.1.2 Regulation of cis-regulatory elements for genomic imprinting 
Imprinted genes are typically found in clusters. Within a cluster, the parental-
specific expression of imprinted genes is coordinately regulated by a cis-regulatory 
element, the imprinting control region (ICR). One hallmark feature of ICRs is parental-
specific differential DNA methylation (Abramowitz and Bartolomei, 2012). Proper 
regulation of imprinted genes is highly dependent on the correct establishment, 
maintenance, and erasure of the differential DNA methylation at ICRs (Figure 1.2) 
Establishment  
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Studies in the mouse germ cells have established that ICRs acquire sperm- or 
oocyte-specific DNA methylation pattern during gametogenesis (Figure 1.2) (Davis et al., 
1999; Lucifero et al., 2004). In both male and female germline, the de novo DNA 
methyltransferase DNMT3a and its accessory protein DNMT3L are required for 
establishing DNA methylation at ICRs (Bourc’his and Bestor, 2004; Bourc’his et al., 
2001; Kaneda et al., 2004; Kato et al., 2007). How these DNA methylation machinery 
proteins are specifically recruited to the ICRs is currently unclear.  
One hypothesis states that transcription at the ICRs is required for DNA 
methylation establishment. Evidence to support this idea exists in both female and male 
germ lines. At the Gnas imprinted locus, truncation of an upstream transcript Nesp (that 
goes through the ICR of the locus) in the oocyte leads to loss of methylation at the locus 
(Chotalia et al., 2009). This suggests that transcription through the ICR is necessary for 
correctly establishing methylation at this locus. Transcripts crossing other maternally 
methylated ICRs are also found at the Snrpn, Grb10, Igf2r, Impact, Kcnq1, and Zac1 
imprinted loci (Chotalia et al., 2009; Mapendano et al., 2006). Similarly, transcription was 
detected in the male germ cells at the H19/Igf2 locus, where the timing of transcription 
correlated with that of ICR methylation establishment (Henckel et al., 2012). However, 
the upstream signal for transcription in the germ cells as well as precise mechanism of 
how transcription affects ICR methylation establishment remain to be determined. 
Maintenance 
Following fertilization in early embryos, ICRs resist the dynamic DNA methylation 
reprogramming and preserve the parental-allele-specific methylation pattern in somatic 
cells (Figure 1.2). To this end, the maternal factor DPPA3 was shown to maintain DNA 
methylation at several ICRs by interacting with histone H3 lysine (K) residue 9 di-
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methylation (H3K9me2) and/or by suppressing the activity of DNA demethylating ten-
eleven translocation (TET) family enzymes (Bian and Yu, 2014; Nakamura et al., 2012). 
The zinc finger protein ZFP57, which interacts with TRIM28, was shown to protect ICRs 
from DNA demethylation (Li et al., 2008; Messerschmidt et al., 2014; Riso et al., 2016). 
The DNA methylation maintenance enzyme DNMT1 methylates newly replicated DNA, 
maintaining methylation at ICRs during cell divisions (Li et al., 1993).  
In order to maintain the differentially methylated status of the ICRs, the 
hypomethylated allele needs to be protected from aberrantly gaining methylation in 
somatic cells. Activating post-translational histone modification marks seem to play 
major role in this regard (discussed below). Yet, one trans factor that carries out this 
function is the methylation-sensitive zinc-finger protein CTCF (Holwerda and de Laat, 
2013). Inability to bind CTCF at the ICR of the H19/Igf2 imprinted locus caused aberrant 
ICR hypermethylation (Engel et al., 2006). Mechanistically, a few groups proposed that 
CTCF can activate PARP1, which can add ADP-ribose groups to DNMT1 and inactivate 
the maintenance methyltransferase (Guastafierro et al., 2008; Yu et al., 2004; Zampieri 
et al., 2012). However, this argument needs to be revisited because the presence or 
absence of the ADP-ribolysated form of CTCF might be tissue-specific (Ideraabdullah et 
al., 2014).   
Erasure     
In order to establish the sex-specific methylation pattern in mature gametes, it is 
important that the established somatic ICR methylation is erased in primordial germ cells 
(PGCs) (Figure 1.2). During this process, both passive (methylation that is lost due to 
the absence of active DNMT1) and active mechanisms were shown to be involved. 
Specifically, TET1 and TET2 enzymes are necessary to actively demethylate ICRs at 
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multiple imprinted loci (Messerschmidt et al., 2014). To do this, TET proteins catalyze 
oxidation of methylated cytosine into hydroxymethylated cytosine, and possibly further 
oxidized species, and the base excision repair pathway is activated to further remove the 
oxidized forms of cytosine (Dawlaty et al., 2013; Hackett et al., 2013; Pastor et al., 2013). 
Studying ICR methylation erasure and re-establishment requires access to early (and 
limited) germ cells. Thus, most of the above findings were from mouse studies. Yet, 
recent studies in human prenatal germ cells illustrate remarkable similarity in DNA 
demethylation/re-methylation dynamics between the mouse and human germlines, 
emphasizing that the ICR reprogramming is a conserved fundamental process in 
mammalian development (Gkountela et al., 2015; Guo et al., 2015; Tang et al., 2015).    
Histone modifications and genomic imprinting 
In addition to DNA methylation, parental allele-specific histone modifications 
have been described at ICRs in both somatic and germ cells (Delaval et al., 2007; Singh 
et al., 2013; Stewart et al., 2015; Verona et al., 2008). Increasing evidence suggests that 
histone modification composition can affect the extent of DNA methylation at ICRs 
(Abramowitz and Bartolomei, 2012). For example, it was shown that oocytes lacking 
KDM1B, a H3K4 demethylase, failed to establish DNA methylation at several ICRs 
(Ciccone et al., 2009). This is consistent with the well-established antagonistic 
relationship between DNA methylation and the activating histone marks such as 
H3K4me2 and H3K4me3 at both imprinted and non-imprinted loci (Meissner et al., 2008; 
Ooi et al., 2007; Singh et al., 2013; Stewart et al., 2015). Importantly, Hajkova et al. 
illustrated that extensive histone modification erasure occurs in PGCs (Hajkova et al., 
2008), suggesting that epigenetic reprogramming during this stage also occurs at a 
chromatin level. The mechanisms by which histone modifications are deposited or 
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removed at ICRs are currently unknown. However, it is quite evident that proper 
establishment and erasure of histone modifications at ICRs is equally vital as that of 
DNA methylation for correct regulation of imprinting. Indeed, various imprinting disorders 
are associated with altered histone modification profiles at ICRs (Nativio et al., 2011).   
Which epigenetic mark (i.e. DNA methylation or histone modifications) works as 
the “primary” signal for distinctly marking each parental allele to regulate imprinted gene 
expression is an active area of research in the field. This could be locus-dependent. 
Overall, understanding the relationship between the two epigenetic modifications in 
regulating genomic imprinting will tremendously contribute to the field of imprinting. 
1.1.3 Evolution and conservation of imprinting control regions (ICRs) 
Imprinted genes are conserved in mammals and differentially methylated ICRs 
play fundamental roles in genomic imprinting. This has led researchers to elucidate the 
molecular bases of the evolution of imprinted genes by examining orthologous ICR 
sequences between different mammalian species. Comparative sequence analyses 
conducted by Suzuki et al. illustrated that novel CpG-rich sequences (which form the 
now called ICRs) emerged at different time points during mammalian evolution in various 
imprinted regions. These sequences emerged predominantly during eutherian evolution 
following the marsupial-eutherian split, suggestive of the evolutionary timeline during 
which functional imprinted genes were established (Suzuki et al., 2011).  
One potential mechanism by which the novel CpG-rich sequences (or ICRs) are 
gained is via retrotransposition. This hypothesis stems from the fact that these 
sequences are 1) similar to transposable elements in that they are enriched with CpG 
sites and 2) subject to DNA methylation in the gametes, a mechanism reminiscent of the 
conserved epigenetic host defense mechanism against foreign DNA (e.g., transposable 
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elements) in the germ cells (Barlow, 1993; McDonald et al., 2005). In fact, previous 
reports have found evidences of retrotransposition of several imprinted genes including 
Peg10, Mcts2, Nap1L5, Inpp5f_v2, U2af1-rs1, and Nnat. These studies lead to the 
speculation that ICRs likely emerged at the same time as the retrotransposition of each 
imprinted gene (Suzuki et al., 2011). However, not all currently identified ICRs display 
evidence of retrotransposition, suggesting that other unknown mechanisms could 
promote acquisition of these regulatory elements in imprinted regions. 
Interestingly, after the novel CpG-rich sequences in imprinted regions were 
acquired, some underwent genetic and/or epigenetic changes over time. For instance, 
the CpG-rich sequences of Slc38a4, Snrpn, and Gnas became differentially methylated 
only in the eutherian lineage (thus fulfilling the prerequisites of being designated as 
ICRs) although the CpG-rich sequences were established earlier. In addition, the 
number of CpG sites within the orthologous ICR sequences of Grb10 increased during 
mammalian evolution, while overall sequence homology was maintained (Suzuki et al., 
2011). These observations suggest that some selective pressure could have acted on 
ICRs and/or imprinted regions, contributing to their evolution at a molecular level.  
Consistent with the fact that imprinted genes and ICRs have greatly expanded 
during eutherian evolution, mouse and human exhibit extensive conservation of 
imprinted genes by sharing key features of imprinting and spatial organization of cis-
regulatory elements. However, ICRs are often divergent between human and mouse, 
raising an interesting question of whether the diverged ICR sequences have any 
functional species-specific significance. One approach that can be exploited to address 
this question is to substitute the ICR sequence of one species with that of another 
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species at the orthologous locus. We took this strategy in specifically probing the 
H19/Igf2 imprinted locus (described in detail below), as discussed in Chapter 2.     
1.2 Imprinted clusters on mouse distal chromosome 7/human 11p15 
Two highly conserved imprinted clusters—H19/Igf2 and Cdkn1c/Kcnq1ot1 loci—
are located in mouse distal chromosome 7 which is syntenic to the human 11p15 region 
(Figure 1.3 and Figure 1.4). These chromosomal regions epitomize genomic imprinting 
for various reasons: 1) Both maternally and paternally methylated ICRs are found, 2) the 
two major mechanisms of imprinting—insulator model and long non-coding RNA 
(lncRNA) model—are used, 3) genetic/epigenetic alterations affecting the ICRs are 
associated with major growth-related imprinting disorders. Thus, various scientific 
endeavors were pursued to elucidate genomic imprinting in these regions. Most notably, 
these imprinted regions are involved in growth regulation in both normal and pathological 
contexts. Therefore, mechanisms of imprinting at the H19/Igf2 and Cdkn1c/Kcnq1ot1 loci 
as well as their involvement in growth regulation are discussed in detail below.  
1.2.1 H19/Igf2 imprinted locus 
H19  
H19 is a maternally expressed ~2.5kb lncRNA (Bartolomei et al., 1991) and is 
one of the few imprinted genes conserved in marsupials. Although the extent of 
sequence similarity between the marsupial and eutherian H19 gene is very low, the 
exonal structure is highly conserved across therians (Figure 1.5A). In fact, H19/Igf2 is 
the most ancient imprinted cluster identified to date (Smits et al., 2008). Despite the well-
known conservation of the gene, functions of H19 in different tissues/physiological 
contexts seem to vary and remain to be further investigated. H19 is abundantly 
expressed in mouse embryonic endodermal and mesodermal lineage tissues as well as 
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in placenta, but expression rapidly declines after birth (Bartolomei et al., 1991; Milligan et 
al., 2000). The best characterized function of H19 is its role in growth suppression during 
fetal and placental development; mouse models lacking H19 display embryonic and 
placental overgrowth with no other apparent phenotypes (Ripoche et al., 1997; Schmidt 
et al., 1999).  
The mechanism by which H19 lncRNA regulates growth remains largely 
unknown. Yet, one recent study proposed that H19 suppresses placental growth via 
maternally expressed microRNA (miR)-675 encoded within the first exon of H19 (Figure 
1.5A) (Keniry et al., 2012). Here, two distinct miRs—miR-675-5p and miR-675-3p—are 
produced (Figure 1.5B). miR-675 is most highly expressed in mouse late gestation 
placenta (its expression peaks around embryonic day (E) 19.5) while it is lowly 
expressed in other fetal tissues (Keniry et al., 2012). Such a dissimilar spatiotemporal 
expression pattern between H19 and miR-675 suggests that despite sharing the same 
transcription unit and the seemingly overlapping role in growth suppression, expression 
of each factor might be regulated and function via different mechanisms. Keniry et al. 
suggests RNA-binding protein HuR as one factor that regulates processing of miR-675 
from H19 (Keniry et al., 2012). This study also demonstrated that overexpression of miR-
675 in various embryonic and extra-embryonic cell lines reduced cell proliferation (Keniry 
et al., 2012). However, testing the role of miR-675 independent of H19 needs to be 
carried out in vivo to dissect the potentially distinct role of each factor in growth 
regulation during development.  
H19 has also been suggested to regulate a network of imprinted genes (known 
as the imprinted gene network, IGN) in trans to control embryonic growth (Gabory et al., 
2009; Varrault et al., 2006). This was hypothesized because modulation of H19 altered 
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expression of other growth-related imprinted genes such as Igf2, Dlk1, Rtl1, Gnas, Peg3, 
Slc38a4, Cdkn1c, and Igf2r (Gabory et al., 2009). The extent to which the changes in the 
IGN gene expression is directly/indirectly regulated by H19 is unclear. Monnier et al. 
showed that H19 can physically interact with the methylated CpG binding protein MBD1 
and repress a subset of IGN genes by modulating H3K9me2 level in vitro (Monnier et al., 
2013). Yet, this experiment requires validation in vivo. Moreover, whether such a change 
in imprinted gene expression is merely a secondary effect caused by changes in cell 
composition and/or number needs to be validated at a single cell level. Nevertheless, the 
idea of coordinate regulation of imprinted genes is gaining attention, as it has been 
described during muscle regeneration and lung stem cell self-renewal as well (Al Adhami 
et al., 2015; Patten et al., 2016; Zacharek et al., 2011). Perhaps this concept fits well 
with the original hypotheses on genomic imprinting as a way to fine-tune complex gene 
expression in mammals.     
Igf2 
Igf2 is a paternally expressed fetal growth factor. Similar to H19, Igf2 is 
ubiquitously expressed in embryonic and placental tissues (Engström et al., 1998). IGF2 
binds to the non-signaling receptor IGF2R (which is also imprinted) with high affinity, 
although it can also bind to signaling receptors such as IGF1R and the insulin receptor 
with lower affinity (Bergman et al., 2013). IGF2R acts as a growth suppressor by 
sequestering and degrading circulating IGF2 (Scott and Weiss, 2000), whereas IGF2 
binding to IGF1R promotes growth during fetal development (Baker et al., 1993). The 
fact that IGF2 plays a pivotal role in embryonic growth is evident in the Igf2 knock-out 
mouse models, where mice display embryonic and placental growth restriction with no 
other apparent phenotype (DeChiara et al., 1990; DeChiara et al., 1991).      
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Regulation of imprinting at the H19/Igf2 locus  
Imprinting at the H19/Igf2 locus is regulated by a model known as the insulator 
model (Figure 1.3). This model illustrates that an insulator/enhancer blocker is formed at 
the ICR in an allele-specific manner, preventing the interactions between enhancers and 
promoters. Previous studies demonstrated that H19 and Igf2 share a set of conserved 
mesodermal and endodermal enhancers located downstream of H19 (Ishihara et al., 
2000; Kaffer et al., 2001; Leighton et al., 1995a). The ICR at this locus, called IC1, is 
located between H19 and Igf2. On the maternal allele, the unmethylated IC1 forms an 
insulator by interacting with CTCF (Bell and Felsenfeld, 2000). This prevents the 
interaction of the Igf2 promoters with the downstream enhancers, silencing Igf2 
expression; because the H19 promoter is accessible to the enhancers, only H19 is 
expressed on the maternal allele. On the paternal allele, IC1 is DNA methylated and 
blocks CTCF binding; thus, the insulator does not form and Igf2 is expressed. The IC1 
also plays a role in silencing paternal H19 expression, by spreading methylation across 
the H19 promoter (Tremblay et al., 1997).  
Various mouse models that carry mutations at IC1 have supported the essential 
role of DNA methylation and CTCF binding for proper insulator function of IC1. When the 
paternal IC1 was mutated at CpG sites to deplete DNA methylation, ectopic binding of 
CTCF was observed on the paternal allele, leading to biallelic H19 expression and 
reduced Igf2 expression (Engel et al., 2004). When the CTCF binding sites were deleted 
on the maternal IC1 to disrupt the insulator, biallelic Igf2 expression and reduced H19 
expression was observed (Engel et al., 2006). These studies demonstrate that any 
insults leading to aberrant DNA methylation or CTCF binding at the IC1 can disrupt 
imprinted expression at the H19/Igf2 locus. 
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Other trans-factors have also been proposed to maintain proper insulator 
function of IC1, although these hypotheses mostly remain controversial. One such factor 
is ZFP57, whose binding motifs reside in both mouse and human IC1. ZFP57 was 
shown to play a role in maintaining DNA methylation at imprinted loci such as Dlk1-Dio3, 
Peg1, Peg3, and Nnat (Li et al., 2008). Conflicting results were presented by two 
studies: IC1 methylation was unaffected in ZFP57-deficient mice yet affected in the 
zfp57-null mouse embryonic stem cells (ESCs) (Li et al., 2008; Riso et al., 2016). In 
addition, patients that have mutations in ZFP57 do not display methylation defects at IC1 
(Mackay et al., 2008). Thus, further studies are warranted to assess the role of ZFP57 in 
IC1 insulator function. 
Pluripotency factors such as OCT4 and SOX2 are also proposed as candidates 
for regulating IC1 function. OCT4-and SOX2-binding sites are present at both mouse 
and human IC1 (Shmela and Gicquel, 2013). OCT4-binding sites at the mouse IC1 were 
shown to be important for maintaining hypomethylated state of IC1 in mouse embryonal 
carcinoma cell line (Hori et al., 2002). However, a mouse model that harbors 0.9kb IC1 
fragment deletion (which also deleted the OCT4-binding sites) showed no perturbation of 
imprinting at the locus (Ideraabdullah et al., 2011). Interestingly, a mouse model with 
endogenous OCT4 binding site mutations at the IC1 displayed partial gain of methylation 
during post-zygotic stages, without affecting monoallelic H19 and Igf2 expression 
(Zimmerman et al., 2013). Therefore, the extent to which OCT4-and/or SOX2-binding 
sites contribute to the insulator function of IC1 awaits further investigation.    
H19/Igf2 locus is the only imprinted locus that uses a well-defined insulator 
model of imprinting. Although CTCF binding sites have been described at other 
imprinted regions including the Grb10, Rasgrf1, Dlk1-Dio3, and Cdkn1c/Kcnq1ot1 loci 
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(Lin et al., 2011; Plasschaert and Bartolomei, 2014; Yoon et al., 2005), it is unknown 
whether these loci utilize the similar insulator model as the H19/Igf2 locus. 
1.2.2 Cdkn1c/Kcnq1ot1 imprinted locus 
The Cdkn1c/Kcnq1ot1 imprinted locus includes at least 8-10 maternally 
expressed protein coding genes (Figure 1.4). Some of these genes are ubiquitously 
imprinted whereas others are imprinted specifically in placenta. A few genes implicated 
in growth regulation are discussed below.  
Cdkn1c  
Cdkn1c is a maternally expressed cyclin-dependent kinase inhibitor. The gene is 
expressed and imprinted in derivatives of all three germ lineages during mouse 
embryonic development, primarily in cells that are exiting the cell cycle (Tunster et al., 
2011). Cdkn1c is a major growth suppressor in the Cdkn1c/Kcnq1ot1 imprinted cluster. 
Mice lacking Cdkn1c displayed embryonic and placental overgrowth during mid-late 
gestation (Tunster et al., 2011). Overexpression of Cdkn1c alone in transgenic mice 
could lead to embryonic lethality. In the same study, the level of the fetal growth factor 
Igf1 transcript was concomitantly altered upon changes in the dosage of Cdkn1c 
(Andrews et al., 2007), suggesting that growth regulation of Cdkn1c could in part be 
achieved via Igf1. Other suggested roles of Cdkn1c during development include cell 
differentiation, migration, and modification of actin cytoskeleton (Andrews et al., 2007; 
Hatada and Mukai, 1995; Tunster et al., 2011).  
Ascl2 and Phlda2 
Ascl2 and Phlda2 are maternally expressed genes that are exclusively imprinted 
and/or preferentially expressed in placenta. Ascl2 is a transcription factor that is 
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essential for cell proliferation in placenta (Guillemot et al., 1995), whereas Phlda2 is a 
cytoplasmic protein that negatively regulates placental growth (Frank et al., 2002). 
Because placenta is an essential organ for maternal-offspring nutrient exchange (Frost 
and Moore, 2010), proper regulation of placental development is indispensable for 
normal embryonic growth.      
Kcnq1ot1 and the regulation of imprinting at the Cdkn1c/Kcnq1ot1 locus  
In some imprinted regions, including the Cdkn1c/Kcnq1ot1, Igf2r, and Snrpn loci, 
parental allele-specific lncRNAs have been identified and were shown to play a role in 
silencing genes in cis (Lee and Bartolomei, 2013). This mechanism of imprinting is 
known as the lncRNA model and is more widely used than the insulator model. In this 
model, lncRNAs are expressed from the ICRs and this expression depends on the 
methylated status of the ICRs (i.e. when ICR is methylated, lncRNA is silenced; when 
unmethylated, lncRNA is expressed) (Figure 1.4). Subsequently, lncRNAs can silence 
the genes in cis by interfering with transcription of the nearby genes or by promoting 
repressive chromatin environment at the imprinted locus (Lee and Bartolomei, 2013).      
Kcnq1ot1 is a ~91kb lncRNA expressed from the paternal allele that has no 
known physiological function (Kanduri, 2011). Its transcription initiates from the ICR of 
the Cdkn1c/Kcnq1ot1 locus, called IC2, in an antisense orientation. IC2 is located in 
intron 10 of the Kcnq1 gene and is methylated on the maternal allele; thus, Kcnq1ot1 is 
silenced on the maternal allele and the cis-genes are expressed (Kanduri, 2011).  
Although Kcnq1ot1 is ubiquitously expressed, its mode of action seems to be 
tissue-specific (i.e. placenta-specific and ubiquitously imprinted genes seem to be 
regulated differently) (Umlauf et al., 2004; Wagschal et al., 2008). Previous studies 
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proposed that Kcnq1ot1 can perform bi-directional silencing on the paternal allele by 
modulating histone modification enrichment at the placenta-specific imprinted genes at 
the locus. These genes are enriched with the paternal allele-specific H3K27me3 and 
H3K9me2 (Lewis et al., 2004; Umlauf et al., 2004). In the Kcnq1ot1 truncation mutant, 
enrichment of H3K27me3 was affected at these sites (Pandey et al., 2008). 
Coimmunoprecipitation and RNA fluorescent in situ hybridization (FISH) experiments 
suggested that Kcnq1ot1 potentially interacts with various histone modifiers such as 
G9A (H3K9 methyltransferase), PRC2 complex (catalyzes H3K27 methylation), and 
RNF2 (ubiquitin E3 ligase) (Pandey et al., 2008; Terranova et al., 2008). Consistently, 
when G9A was knocked out, partial loss of H3K9me2 and H3K9me3 at the locus was 
observed (Wagschal et al., 2008). These results suggest that Kcnq1ot1 regulates 
imprinting in placenta by interacting with various histone modifiers.  
On the other hand, Kcnq1ot1 seems favor a different epigenetic modification—
DNA methylation—in silencing the ubiquitously imprinted genes at the locus, such as 
Cdkn1c and Slc22a18 (Lewis et al., 2004). To support this idea, somatically established 
differentially DNA methylated regions (DMRs) are only found around Cdkn1c and 
Slc22a18, but not at the placenta-specific imprinted genes (Lewis et al., 2004). 
Mohammad et al. illustrated that Kcnq1ot1 can recruit DNMT1 to these DMRs to 
maintain methylation (Mohammad et al., 2010). In addition, both Cdkn1c and Slc22a18 
were biallelically expressed in Dnmt1-null embryos and placentas. Notably, monoallelic 
expression of the placenta-specific imprinted genes Cd81, Osbpl5, and Tssc4 was 
barely affected by loss of DNMT1, suggesting that imprinting in placenta minimally relies 
on DNA methylation (Lewis et al., 2004).  
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It is unlikely that all lncRNA imprinting models function via altering chromatin 
environment. For example, Airn is a paternally expressed antisense lncRNA at the Igf2r 
imprinted locus. One of the cis genes Airn silences is the growth regulator Igf2r. Latos et 
al. showed that Airn silences Igf2r by transcriptional interference, by reducing 
recruitment of RNA polymerase II to the Igf2r promoter (Latos et al., 2012). Thus, in this 
case, the act of transcription per se is more important for imprinting than the lncRNA 
transcript itself.   
In conclusion, the lncRNA model of imprinting seems to be more versatile in its 
mechanisms of action and is employed by more imprinted loci. Further studies should 
address questions such as how lncRNAs find their targets, how lncRNAs interact with 
epigenetic modifiers or transcription machinery proteins, and how lncRNA-driven tissue-
specific imprinting is established and maintained.  
1.3 Human disorders associated with 11p15  
Mouse models have held great value for investigating mammalian imprinting 
mechanisms. Nevertheless, the recent identification of various alterations at the 11p15 
region in human imprinting disorder patients has raised new questions about how 
imprinting functions in human health and disease. The ability to model the newly 
discovered alterations will provide additional insights into human imprinting mechanisms 
and potentially assist in therapeutic advances for these disorders. Furthermore, 
comparing the phenotypes of the patients to those of mouse models with similar 
mutations provides clues about the extent to which imprinting mechanisms are 
conserved between the two species.  
As mentioned above, the human 11p15 region is essential for growth regulation. 
Consistently, two major growth-related imprinting disorders—Beckwith-Wiedemann 
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syndrome (BWS) and Silver Russell syndrome (SRS)—are associated with 
misregulation of imprinting in this region. Clinical features and molecular etiologies of 
both disorders are discussed below. 
1.3.1 Clinical features and occurrence rate of BWS and SRS  
BWS (OMIM 130650) is a pediatric overgrowth disorder with an estimated 
frequency of 1/10,500 per live births, affecting males and females equally, making it the 
most common imprinting disorder (Choufani et al., 2013; personal communication with 
Jennifer Kalish, MD, PhD at Children’s hospital of Philadelphia (CHOP)). Major clinical 
features include enlarged tongue, hemihyperplasia (asymmetric overgrowth), and 
abdominal wall defects (Weksberg et al., 2010). Notably, some BWS individuals develop 
embryonal tumors, most commonly Wilms tumor (kidney cancer) and hepatoblastoma 
(liver cancer) (Choufani et al., 2013). 
SRS (OMIM 180860) is a rarer pediatric growth failure disorder with more than 
400 cases being reported since its first description in 1953 (Silver et al., 1953; Russell, 
1954; Ishida, 2016). Major clinical features include intrauterine growth restriction, 
hemihypoplasia (asymmetric undergrowth), and relative macrocephaly (Ishida, 2016).  
In both BWS and SRS, the reported occurrence rate could be an underestimation. 
Improved sensitivity of molecular diagnostic techniques used in the clinic to analyze 
DNA methylation aberration, chromosomal rearrangements, and percent mosaicism of 
affected cells has increased the chances of detecting understated molecular signatures 
in the patients. In addition, the spectrum of clinical phenotypes is now better 
characterized, which enables clinicians to recognize individuals with subtler clinical 
features (personal communication with Jennifer Kalish, MD, PhD at CHOP). These 
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improvements in the medical setting are invaluable to the patients and their families and 
widen opportunities to dissect human imprinting mechanisms. 
BWS and SRS patients display a wide spectrum of clinical phenotypes (Ishida, 
2016; Weksberg et al., 2010). This may occur either as a consequence of the mosaic 
distribution of affected cells or the genetic background of the individuals (Beygo et al., 
2013; Kalish et al., 2013; Kannenberg et al., 2012). Thus, studies of imprinting 
mechanisms in the context of human disorders need to control for the mosaicism and 
genetic background in the patients. One way such issues can be addressed is by 
deriving patient-specific induced pluripotent stem cells (iPSC) lines, as discussed in 
Chapter 3. 
1.3.2 Molecular etiology of BWS  
 Various BWS-associated molecular alterations have been described, including 
genetic and epigenetic alterations and chromosomal abnormalities (Figure 1.6) (Soejima 
and Higashimoto, 2013; Weksberg et al., 2010).  
 Alterations in the CDKN1C/KCNQ1OT1 locus are prevalent among BWS 
individuals. In fact, the most common alteration found in BWS population (~50%) is IC2 
hypomethylation (Figure 1.6). Because IC2 is never completely hypomethylated in each 
patient, the epimutation is assumed to occur mosaically, which is a common 
characteristic of majority of epimutations found in imprinting disorders (Soejima and 
Higashimoto, 2013; Ishida, 2016). IC2 hypomethylation is accompanied by loss of H3K9 
methylation at IC2, biallelic KCNQ1OT1 expression, and loss of CDKN1C expression 
(Diaz-Meyer et al., 2003; Higashimoto et al., 2003). This phenotype can be explained by 
the Cdkn1c/Kcnq1ot1 imprinting mechanism that was elucidated in mouse models, 
suggesting that a similar imprinting mechanism is used in humans. The overgrowth 
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phenotype found in these patients is most likely driven by loss of CDKN1C, as various 
CDKN1C mutations leading to loss of function of the protein are also found in small 
subset (~5%) of BWS patients (Hatada et al., 1996; Romanelli et al., 2010).  
 Although alterations involving the H19/IGF2 locus are less common, they are 
associated with increased risk of tumor development. About 2-7% of BWS cases display 
IC1 hypermethylation (Soejima and Higashimoto, 2013). Notably, an increasing number 
of studies are finding genetic alterations associated with IC1 hypermethylation (Figure 
1.6 and Figure 1.7). One type of mutation is IC1 microdeletions that remove different 
sequences and numbers of CTCF binding sites (CTS). In these patients, when the 
mutation is maternally inherited, IGF2 is biallelically expressed and H19 expression is 
reduced, suggestive of a loss of insulator function (Beygo et al., 2013; Prawitt et al., 
2005; Sparago et al., 2004). These phenotypes are reminiscent of the mouse models 
with partial deletions of the IC1 sequence. In these models, IC1 was hypermethylated at 
the remaining IC1 and biallelic Igf2 expression was observed upon maternal inheritance 
of the mutant allele (Engel et al., 2006; Thorvaldsen et al., 1998). These results suggest 
that the imprinting mechanism at the H19/IGF2 locus is largely conserved between 
human and mouse.     
Point mutations of the OCT4-SOX2-binding motif have also been identified 
among BWS individuals with IC1 hypermethylation (Figure 1.7). Maternal transmission of 
the mutant alleles is associated with clinical phenotypes in the patients (Demars et al., 
2010; Habib et al., 2014; Poole et al., 2012). As mentioned previously, studies 
investigating the role of the mouse OCT4-binding sites in the insulator function of IC1 
presented ambiguous results. Similarly, inconsistent arguments were made regarding 
the role of human OCT4-binding sites in the function of IC1. Mutating the OCT4-binding 
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sites on human IC1 minimally affected the enhancer-blocking and CTCF-binding 
activities of IC1 in vitro (Beygo et al., 2013). In contrast, human IC1 sequence with 
OCT4-binding site mutation impaired the ability of IC1 to bind human OCT4/SOX2 
proteins in vitro, suggesting that the binding of these proteins has a functional role at IC1 
(Demars et al., 2010). Overall, the contribution of OCT-SOX-binding sites to the insulator 
function of IC1 remains unknown in both mouse and human. However, it is possible that 
1) the ability of OCT4-SOX2-binding motifs to control IC1 methylation depend on the 
non-conserved sequence of IC1 between mouse and human and thus be species-
specific 2) OCT4 mutations may predispose patients to BWS via unidentified mechanism 
(Zimmerman et al., 2013).    
Lastly, paternal uniparental isodisomy of chromosome 11 (pUPD11) is found in 
about 20% of BWS cases and normally includes both H19/IGF2 and 
CDKN1C/KCNQ1OT1 loci. pUPD11 occurs when part or entire of the maternal 
chromosome 11 is lost in a single cell. To repair the missing chromosome or 
chromosome portion, a duplication of the corresponding region of the paternal 
chromosome occurs. This rescue event leads to both copies of chromosome 11 having 
the paternal epigenotype, resulting in IC1 hypermethylation, IC2 hypomethylation, 
increased IGF2 expression, and reduced H19 and CDKN1C expression (Kalish et al., 
2014)) (Figure 1.8). The majority of pUPD11 BWS cases display mosaicism, indicating 
that these alterations arise post-zygotically (Kalish et al., 2014). Interestingly, pUPD11 
patients are more predisposed to tumor development (Kalish et al., 2014). Despite being 
one of the common origins of BWS, no models to study pUPD11 exist in the field. This is 
largely due to the difficulty of engineering such chromosomal lesions as well as the 
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mosaic nature of UPD in patient samples. In Chapter 3, we describe a human cell-based 
model system that can be used to investigate pUPD11 and BWS.  
1.3.3 Molecular etiology of SRS  
 The most common alteration associated with SRS is IC1 hypomethylation (Figure 
1.6) (Ishida, 2016). Given the established model of imprinting at the H19/Igf2 locus in 
mouse, this epimutation is proposed to reduce IGF2 expression and increase H19 
expression. Indeed, a mouse model depleted of methylation at IC1 had biallelic H19 
expression, reduced Igf2 expression, and 40% reduction in the size of the animals 
(Engel et al., 2004). Consistently, Gicquel et al. observed that patients with IC1 
hypomethylation exhibited reduced IGF2 and biallelic H19 expression (Gicquel et al., 
2005). However, results from other human studies have led to ambiguous conclusions 
about the exact mechanisms underlying SRS with IC1 hypomethylation. For example, 
Azzi et al. did not observe difference in IGF2 expression between IC1 hypomethylation 
and unaffected patients’ fibroblasts. Moreover, total H19 expression level did not 
correlate with the degree of IC1 methylation (Azzi et al., 2014). Heckmann et al. did not 
detect differences in IGF2 protein secretion nor H19 expression between IC1 
hypomethylation and unaffected fibroblasts; instead, cells with IC1 hypomethylation 
exhibited aberrantly expressed genes involved in cell proliferation, cell cycle control, and 
timing of mitosis (Heckmann et al., 2015). Such discrepancies between human studies 
could be due to mosaic nature of the epimutation as well as the use of disease-irrelevant 
tissues, such as blood and fibroblasts, where H19 and IGF2 are lowly expressed.  
 Maternal UPD of chromosome 7 (mUPD7) accounts for ~10% of SRS cases 
(Figure 1.6) (Bartholdi et al., 2009). mUPD7 encompasses imprinted genes such as 
GRB10, CPA4, MEST, KLF4, MEST1T1, and COPG21T1 (Ishida, 2016). However, no 
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known single mutation of any of these genes has been identified to date, although 
possible involvement of epimutations cannot be excluded (Ishida, 2016). Of note, 
maternally expressed Grb10 suppresses growth in the mouse (Plasschaert and 
Bartolomei, 2014). In study by Leach et al., individuals with mUPD7 in which GRB10 
was excluded from the duplicated region, did not display SRS growth failure phenotypes; 
this implies that GRB10 might be involved in pathogenesis of SRS (Leach et al., 2007).  
1.4 Challenges in studying imprinting mechanisms 
Mouse models are extremely advantageous in investigating imprinting 
mechanisms because parent-of-origin transmission of an imprinted allele can be tested. 
Moreover, access to early germ cells such as PGCs allows monitoring of epigenetic 
reprogramming at ICRs, the most essential aspect of imprinting regulation. However, 
mouse models with endogenous ICR mutations often do not fully recapitulate human 
phenotypes associated with mutations at the orthologous locus. Various Cdkn1c loss of 
function mouse models do not present neonatal overgrowth phenotype of BWS (Tunster 
et al., 2011). A mouse model that carries 1.3kb deletion at IC1, generated to model IC1 
microdeletions in human, exhibits biallelic Igf2 expression with no changes in IC1 
methylation (Ideraabdullah et al., 2014). Furthermore, biallelic Igf2 expression is only 
observed in tissues of mesodermal origin (Ideraabdullah et al., 2014). Imprinting 
mechanisms seem to be generally conserved between mouse and human. However, it is 
possible that across evolution from mouse to human, certain aspects of imprinting have 
diverged. Tunster et al. speculate that differences in the reproductive strategies (i.e. 
multiparous in mouse and singleton pregnancy in human) might have driven the 
divergence (Tunster et al., 2011). Thus, mouse models alone might not be sufficient to 
fully comprehend human imprinting mechanisms. 
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As a complementary approach, various studies were conducted using patient 
samples to investigate imprinting mechanisms and/or disease etiology. However, human 
studies have led to varying conclusions. Such discrepancy can result from 1) the use of 
blood and/or fibroblasts samples that are often irrelevant to disease (by expressing 
genes of interest at a very low level), 2) mosaic nature of the genetic mutations or 
epimutations. In line with this idea, studies have shown that the degree of DNA 
methylation alterations in BWS and SRS can be tissue-, cell-, and CpG site-specific, 
regardless of presence of genetic lesions (Beygo et al., 2013; Kannenberg et al., 2012). 
Therefore, model systems in which mosaicism can be controlled in a disease-relevant 
cell types are best suited to investigate mechanisms of imprinting.  
The overall goal of this dissertation is to develop and explore model systems to 
study imprinting mechanisms. We have developed both in vivo and in vitro models with 
initial interest in modeling human imprinting mechanisms, focusing on the human 11p15 
imprinted loci. Beyond serving as platforms to study imprinting mechanisms, these 
models allowed us to speculate on the evolutionary perspective of imprinting as well as 
epigenetic vulnerability in cell culture models.  
Chapter 2 describes an in vivo mouse model where human IC1 sequence 
replaces the orthologous mouse sequence. We find that the human and mouse 
imprinting mechanism at the H19/IGF2 locus has partially diverged. We also propose 
that this mouse model may serve to study mechanisms of IC1 hypomethylation 
associated with SRS. Chapter 3 describes an iPSC model derived from the fibroblasts of 
pUPD11 patients with BWS. These cell lines display the expected and stable epigenetic 
signatures at the pUPD11-relevant region, making them suitable models to study 
mechanisms underlying pUPD11 leading to BWS. However, we find that one imprinted 
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locus that frequently exhibits loss of imprinting in other iPSC models is similarly 
misregulated in our cell lines, although the significance of this phenotype is unclear.  
Importantly, both models overcome issues related to mosaicism: the mouse 
model displays full penetrance of the epigenetic/genetic phenotype, and the iPSC lines 
are clonally-driven. Moreover, cell types of interest are readily accessible/can be derived 
from both models. Therefore, the work in this thesis emphasizes the utility of both 
mouse/human as well as in vivo and in vitro complementary approaches in studying 
imprinting mechanisms.   
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Figure 1.1 Genomic imprinting. Majority of the mammalian genes (purple boxes) are expressed 
from both parental alleles. However, imprinted genes (red and blue boxes) are expressed in a 
monoallelic, parent-of-origin specific manner. The blue box represents a paternally expressed 
imprinted gene, and the red box represents a maternally expressed imprinted gene. Expression is 
indicated by arrow, and silenced genes are illustrated in grey boxes. The parent-of-origin of the 
allele is indicated with a female(♀) or a male (♂) symbol on the left. 
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Figure 1.2 DNA methylation reprogramming at ICRs. The figure illustrates a scheme for a 
paternally methylated ICR (yellow box). During germ cell development, sex-specific DNA 
methylation pattern (filled lollipops represent methylated CpGs; empty lollipops represent 
unmethylated CpGs) is established at the ICR. Following fertilization, the parental-allele specific 
ICR methylation is maintained in somatic cells; the parent-of-origin of the ICR is indicated with a 
female(♀) or a male (♂) symbol next to the ICR in diploid nuclei. In the primordial germ cells 
(PGCs) of a growing embryo, somatic methylation pattern is erased, allowing re-establishment of 
a sperm- or oocyte-specific methylation at the ICR. The figure is adapted from Weaver et al. 
(Weaver et al., 2009) 
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Figure 1.3 Insulator model of imprinting at the H19/Igf2 locus in mouse. On the maternal 
allele (♀), CTCF binds to the unmethylated IC1, Igf2 expression is blocked, and H19 is expressed. 
On the paternal allele (♂), the IC1 is methylated, CTCF does not bind, Igf2 is free to interact with 
the downstream enhancers and is expressed; H19 is silenced due to methylation at its promoter. 
Centromeric (C) and telomeric (T) ends are indicated. Not drawn to scale. 
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Figure 1.4 LncRNA model of imprinting at the Cdkn1c/Kcnq1ot1 locus in mouse. On the 
maternal allele (♀), Kcnq1ot1 is not expressed due to methylated IC2; thus, adjacent imprinted 
genes are expressed. On the paternal allele (♂), unmethylated IC2 allows the expression of 
Kcnq1ot1; Kcnq1ot1 silences genes in cis bidirectionally. Only imprinted genes are labeled. 
Centromeric (C) and telomeric (T) ends are indicated. Not drawn to scale.  
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Figure 1.5 H19 and miR-675 in therians. (A) Scale illustration of H19 gene in eutherians 
(human and mouse) and marsupials (wallaby and opossum). Although sequence conservation 
between eutherians and marsupials is low, the exonal structure of the gene is largely conserved 
in therians. Each exon (E) is depicted in red box. The conserved miR-675 sequence is 
represented in pink box within E1. (B) Shown is the precursor regions of the conserved miR-675 
in human and mouse. The predicted mature forms of the miR-675-5p and the miR-675-3p are 
underlined. Figures adapted from Smits et al. (Smits et al., 2008). 
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Figure 1.6 Alterations associated with BWS and SRS. In both pie charts, alterations found in 
human 11p15 are represented in colored slices. UPD11: uniparental isodisomy of chromosome 
11; UPD7: uniparental isodisomy of chromosome 7 (Ishida, 2016; Soejima and Higashimoto, 
2013; Weksberg et al., 2010). 
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Figure 1.7 IC1 microdeletions and OCT4-binding site point mutations found in BWS IC1 
hypermethylation cases. Examples of previously reported mutations at the locus. Here, human 
IC1 that has seven CTCF binding site (CTS) is illustrated; CTSs within IC1 are numbered for 
convenience. IC1 microdeletions are depicted in red lines; deletion length and CTS removed by 
the microdeletion are indicated next to each red line. OCT4-binding sites (Oct4 motif: OM) are 
noted with inverted triangles; within OM2, three octamer binding motifs are underlined; point 
mutations are indicated with arrows. Figure modified from Ideraabdullah et al. and Beygo et al. 
(Beygo et al., 2013; Demars et al., 2010; Habib et al., 2014; Ideraabdullah et al., 2008; Poole et 
al., 2012; Prawitt et al., 2005; Sparago et al., 2004). 
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Figure 1.8 pUPD11. A schematic of the 11p15 imprinted loci in non-pUPD11 (top) and pUPD11 
(bottom). Cdkn1c/Kcnq1ot1 locus, regulated by the maternally methylated IC2, is depicted on the 
left, and H19/Igf2 locus, regulated by the paternally methylated IC1, is depicted on the right. For 
simplicity, only selected imprinted genes are shown for the Cdkn1c/Kcnq1ot1 locus. pUPD11 
cells have two copies of paternal allele in this region. The parent-of-origin of the allele is indicated 
with a female(♀) or a male (♂) symbol. Centromeric (C) and telomeric (T) ends are indicated. Not 
drawn to scale.
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CHAPTER 2.                                    
HUMANIZED MOUSE MODEL 
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2.1 Background and study rationale 
Comparative genome studies have revealed extensive conservation of H19/Igf2 
in therians (Smits et al., 2008). Consistently, key features of imprinting, as well as spatial 
organization of the mouse and human loci, are shared, including DNA methylation 
patterns, presence of CTSs at IC1, and downstream enhancers. Notably, however, the 
length of IC1 and the number of CTSs within IC1 have diverged; the ∼5-kb human IC1 
has seven CTSs, whereas the corresponding mouse sequence is ∼2 kb and has four 
CTSs (Figure 2.1). In addition, with the exception of the CTCF-binding motifs, IC1 
exhibits low sequence homology between mouse and human (Jinno et al., 1996; Jones 
et al., 2002). This raises the question of whether the human IC1 sequence could 
successfully regulate H19/Igf2 imprinting in the mouse. If it can, then an in vivo model for 
imprinting disorders associated with mutations at human IC1 could be generated (Figure 
1.7).  
Although interspecies compatibility of human IC1 was previously investigated in a 
transgenic mouse model (Jones et al., 2002), the human transgene failed to exhibit the 
expected imprinting pattern. The transgene acquired DNA methylation in male germ 
cells in a copy number-dependent manner, but the methylation was not stably 
maintained in somatic cells. In addition, the human H19 transgene was abnormally 
expressed on paternal transmission. Interpretation of these observations is complicated 
by transgene copy number variation, however. Furthermore, because long-range 
chromatin looping plays an essential role in H19/Igf2 imprinting (Engel et al., 2008; 
Nativio et al., 2011), the transgene insertion site may influence the phenotype. Thus, it is 
imperative to test the functionality of the human IC1 element at the orthologous locus.  
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Here we generated a knock-in mouse model in which the endogenous mouse 
IC1 (mIC1) was replaced by human IC1 (hIC1). Our goal was to investigate the extent to 
which hIC1 can functionally replace mIC1. We found that hIC1 properly recapitulates 
mIC1 function on the maternal allele, whereas hIC1 fails to properly regulate the 
H19/Igf2 locus on the paternal allele. hIC1 is incompletely methylated in the male germ 
cells of knock-in mice, which is associated with increased enrichment of H3K4me2 at 
hIC1. Overall, this study reveals interspecies incompatibility of hIC1 in the mouse male 
germline. Importantly, we show that abnormal histone modification composition at hIC1 
may affect the proper establishment of DNA methylation at hIC1 during mouse germ cell 
development. 
2.2 Generation of the H19hIC1 allele 
To determine whether hIC1 could functionally substitute for the orthologous 
mouse sequence, we replaced the endogenous mIC1 with hIC1 by gene targeting in 
ESCs (Figure 2.2A). Even though we obtained highly chimeric mice after blastocyst 
injection of the targeted ESCs, germline transmission of the targeted allele was 
inefficient. Only one female pup with the H19hIC1 allele was live-born out of >250 agouti 
pups; all other agouti pups were wild-type, suggesting that the pups inheriting the 
H19hIC1 allele might be dying prenatally. The single live-born female knock-in pup was of 
noticeably smaller size compared with its wild-type siblings and remained small. The 
neomycin resistance cassette (NeoR) was excised by crossing the female to EIIA-Cre 
male on a C57BL/6J (B6) background (Jackson Laboratories). Germ-line transmission of 
the targeted allele and excision of NeoR were confirmed by Southern blot analysis 
(Figure 2.2B). When bred to a B6 male, the female knock-in mouse was fertile, and wild-
type and knock-in progeny were born in the expected Mendelian ratios with no sex bias. 
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Embryonic lethality on paternal transmission was again observed after NeoR excision. 
The use of knock-in males in a B6/CF1 mixed strain for paternal transmission did not 
resolve the embryonic lethality. These results rule out NeoR and pure B6 background as 
being solely responsible for the failure to obtain mutant pups. The H19hIC1 allele was 
maintained through maternal transmission in a B6 background. 
2.3 IC1 imprinting upon maternal transmission of the H19hIC1 allele 
To investigate H19 and Igf2 imprinting when the targeted allele was maternally 
transmitted, we bred female H19hIC1/+ mice to B6 (CAST7) mice, which have a Mus 
musculus castaneus chromosome 7 on a B6 background (Mann et al., 2003). This cross 
allows the parental origin of H19 and Igf2 expression to be distinguished in F1 progeny. 
Heterozygous H19hIC1/+ mice were compared with their wild-type littermates (H19+/+). The 
H19hIC1/+ and H19+/+ mice were born in Mendelian ratios with no sex bias and no 
difference in neonatal weight (Figure 2.3A). We assayed expression and IC1 methylation 
in neonatal livers, where H19 and Igf2 are highly expressed, and detected monoallelic 
expression in all cases (Figure 2.3B). Consistently, total expression levels of H19 and 
Igf2 were statistically equivalent in H19+/+ and H19hIC1/+ livers, as measured by 
quantitative real-time PCR (qRT-PCR) (Figure 2.3C). DNA methylation at hIC1 on the 
maternal allele and endogenous mIC1 on the paternal allele was measured by bisulfite 
mutagenesis of genomic DNA, followed by pyrosequencing. The maternal hICI was 
hypomethylated, as expected (Figure 2.4A). Methylation at several other ICRs in 
H19hIC1/+ livers was normal, suggesting that the general imprinting machinery is 
functioning normally (Figure 2.4B). Finally, hIC1 was properly hypomethylated in the 
oocytes of H19hIC1/+ females (Figure 2.4C). We repeated these analyses in two 
sequential generations of the H19hIC1 allele maternal transmission offspring and obtained 
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the same results. Overall, these data illustrate that hIC1 can functionally replace mIC1 
on the maternal allele. 
2.4 IC1 imprinting upon paternal transmission of the H19hIC1 allele 
To investigate H19 and Igf2 imprinting on the paternal allele, we bred male 
H19hIC1/+ mice to B6 (CAST7) mice. All live-born neonates were wild-type, similar to 
what was observed when breeding for germ-line transmission in chimeric mice, 
suggesting that paternal transmission of the H19hIC1 allele is embryonic lethal. To 
investigate this possibility, we isolated E15.5 conceptuses. Although the H19+/hIC1 
conceptuses were viable, the H19+/hIC1 embryos and placentas were smaller and 
weighed significantly less compared with those of H19+/+ (Figure 2.5A). Anecdotally, 
such a size difference was not apparent at E10.5, and a trend toward a smaller size was 
observed at E12.5. The fetal/placental weight ratio was not different between E15.5 
H19+/+ and H19+/hIC1, demonstrating that H19+/hIC1 tissues were proportionately smaller 
(Figure 2.5B). Allele-specific RNA analysis revealed biallelic H19 in E15.5 H19+/hIC1 livers 
and placentas, with equal expression derived from the two parental alleles (Figure 2.5C 
and E), suggesting complete derepression of paternal H19. In contrast, paternal Igf2 
expression was barely detectable, indicating complete repression of Igf2 (Figure 2.5C 
and E). Consistently, qRT-PCR analyses revealed approximately 3.4-fold and 1.5-fold 
increases of H19 in liver and placenta, respectively, and undetectable Igf2 in H19+/hIC1 
compared with H19+/+ embryos in both tissues (Figure 2.5D and F). Similar results were 
observed in E9.5 whole embryos (Figure 2.5G and H).  
We next examined the extent to which methylation at hIC1 correlated with 
abnormal expression in heterozygous livers and placentas. hIC1 was completely 
unmethylated on the paternal allele, resembling the endogenous mIC1 on the maternal 
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allele (Figure 2.6A and B). This unusual methylation pattern was not due to a gross 
defect in the methylation machinery, because methylation at other ICRs was normal in 
H19+/hIC1 embryos (Figure 2.6C). 
Finally, to determine whether the hypomethylated state of hIC1 is associated with 
ectopic binding of CTCF on the paternal allele, we performed allele-specific chromatin 
immunoprecipitation (ChIP) followed by quantitative real-time PCR (ChIP–qRT-PCR) for 
CTCF in E12.5 mouse embryonic fibroblasts (MEFs). As expected, CTCF bound only to 
the unmethylated hIC1 on the maternal allele and did not bind to the methylated mIC1 
on the paternal allele in H19hIC1/+ MEFs. In contrast, CTCF bound to both the 
unmethylated mIC1 on the maternal allele and the unmethylated hIC1 on the paternal 
allele in H19+/hIC1 MEFs (Figure 2.7). The results demonstrate that paternal hIC1 is 
unable to acquire or maintain the hypermethylated state of endogenous mIC1, fails to 
repress H19, and instead gains a CTCF-dependent insulator function. 
Because the paternal allele in E15.5 H19+/hIC1 embryos was hypomethylated, we 
assayed DNA methylation at earlier stages. We did not detect any methylation at hIC1 
as early as the blastocyst stage (Figure 2.8).  
2.5 DNA methylation at the H19hIC1 allele in the male germline 
The observation that hIC1 was hypomethylated even as early in the blastocyst 
stage embryos suggested that either methylation was not established during 
spermatogenesis or methylation was established but was lost during preimplantation 
development. To distinguish between these possibilities, we examined DNA methylation 
at hIC1 in sperm of H19hIC1/+ males, and observed partial methylation (Figure 2.9A and 
B). As positive controls, we analyzed methylation at endogenous hIC1 in human sperm 
samples from two fertile men as well as at endogenous mIC1 in H19hIC1/+ sperm and 
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found that all were hypermethylated, as expected (Figure 2.9A and B). To explore 
whether the methylation at hIC1 in H19hIC1/+ sperm could be maintained after the first 
cleavage division, we assayed H19+/hIC1 two-cell embryos in which the zygote had 
undergone one round of mitosis. We found reduced methylation levels (close to one-half 
less) at hIC1 in two-cell embryos compared with mature sperm (Figure 2.9A). These 
results demonstrate that the DNA methylation is partially established at hIC1 during 
spermatogenesis, but is not maintained in preimplantation development. 
2.6 Histone modification at the H19hIC1 allele in the male germline 
To investigate factors that may inhibit complete establishment of DNA 
methylation at hIC1 during spermatogenesis, we examined histone modifications at hIC1. 
Parental allele-specific histone modifications have been described at mIC1 in both 
somatic and germ cells (Delaval et al., 2007; Lee et al., 2010; Singh et al., 2013; Stewart 
et al., 2015; Verona et al., 2008). For instance, H3K4 methylation is found preferentially 
on the hypomethylated maternal IC1, and H3K9me3 is found on the hypermethylated 
paternal IC1 in mouse and human somatic cells (Delaval et al., 2007; Nativio et al., 
2011)). The antagonistic relationship between “activating marks” and DNA methylation 
(Ciccone et al., 2009; Ooi et al., 2007; Singh et al., 2013; Stewart et al., 2015) has been 
well-established. Moreover, several studies illustrated a strong relationship between 
“repressive marks,” such as H3K9me3 and DNA methylation (Rose and Klose, 2014). 
Therefore, we hypothesized that depletion of H3K9me3, increased enrichment of 
H3K4me2, or both contribute to the inability to fully establish DNA methylation at hIC1. 
Spermatogenic cells were fractionated by the STA-PUT method, and chromatin was 
isolated from a round spermatid-enriched fraction (Bryant et al., 2013). ChIP–qRT-PCR 
analyses in round spermatids revealed that hIC1 had fivefold greater enrichment of 
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H3K4me2 compared with mIC1 (Figure 2.9C). Unlike previous studies that did not report 
significant enrichment of H3K9me3 above background at mIC1 in the male germ line 
(Delaval et al., 2007; Singh et al., 2013), we obtained a ChIP signal above background. 
This discrepancy could be attributed to the different antisera used for H3K9me3. 
Nevertheless, there was no difference in the enrichment of H3K9me3 between hIC1 and 
mIC1. Our finding that the difference in H3K4me2 between mIC1 and hIC1 is greater 
than the difference in H3K9me3 suggests that (i) H3K9me3 does not affect the 
acquisition of DNA methylation at hIC1 during spermatogenesis, and (ii) enrichment of 
activating histone marks at hIC1 contributes in part to the incomplete establishment of 
imprinting at hIC1 during spermatogenesis (Figure 2.9C). 
2.7 Additional analyses upon paternal transmission of the H19hIC1 allele 
Because H19+/hIC1 embryos display similar phenotypes to many SRS patients that 
present with IC1 hypomethylation including altered H19 and Igf2 expression and growth 
defects (Gicquel et al., 2005; Yamazawa et al., 2008), we hypothesized that these 
embryos can serve as a model for SRS. Thus, we further characterized H19+/hIC1 
embryos and placentas to study potential mechanisms underlying SRS associated with 
IC1 hypomethylation.  
2.7.1 Imprinted gene network (IGN) genes in H19+/hIC1  
We first investigated several IGN genes, focusing on seven genes (maternally 
expressed Cdkn1c, Gtl2, Igf2r, and paternally expressed Dlk1, Gnas, Peg3, Slc38a4) 
whose levels were previously shown to be affected by H19 expression in trans (Gabory 
et al., 2009). In H19+/hIC1 livers, three of the four paternally expressed genes (Dlk1, Gnas, 
Slc38a4) were significantly upregulated, whereas in H19+/hIC1 placentas, two of the three 
maternally expressed genes (Cdkn1c, Gtl2) were downregulated compared to H19+/+, 
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suggesting tissue-specific regulation of IGN genes (Figure 2.10). The changes were 
more subtle in placentas compared to livers. Overall, these results support the 
previously proposed homeostatic role of IGN genes in controlling fetal growth. 
2.7.2 Placental morphology in H19+/hIC1 
Placental growth defects are prevalent among SRS individuals (Yamazawa et al., 
2008). Thus, we performed histological analyses on E15.5 H19+/hIC1 placentas to explore 
whether abnormal placentation could contribute to embryonic growth restriction, given 
that H19 and Igf2 play essential roles in placental development (Bartolomei and 
Ferguson-Smith, 2011; Reik et al., 2003). In addition to being smaller (~74% of H19+/+), 
H19+/hIC1 placentas displayed an increased junctional to labyrinthine zone ratio, indicative 
of abnormal placenta morphology (Figure 2.11A and B). 
2.7.3 miR-675 in H19+/hIC1 
 Lastly, miR-675 was analyzed in the H19+/hIC1 embryos and placentas. The role of 
miR-675 in limiting cell proliferation has been demonstrated in various cell types in vitro 
(Keniry et al., 2012). Thus, we measured the level of miR-675-3p and miR-675-5p in 
E15.5 H19+/hIC1 livers and placentas. Despite being more highly expressed in placentas 
compared to livers, both miR-675-3p and miR-675-5p were elevated only in H19+/hIC1 
livers but not in placentas compared to H19+/+ (Figure 2.12A). These data suggest that in 
addition to greatly reduced Igf2 and increased H19 expression in H19+/hIC1 placentas and 
embryos, increased miR-675 expression in embryos may further restrict the growth of 
embryos.  
 Keniry et al. proposed Igf1r as a potential target of miR-675-3p (Keniry et al., 
2012). To support this idea, Igf1r is upregulated in E18.5 mouse placenta in which H19 
sequence is deleted (Keniry et al., 2012), suggesting that the concurrently deleted miR-
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675 could be repressing Igf1r. Thus, we expected that in H19+/hIC1 livers, where miR-675 
is upregulated, Igf1r would be downregulated. Contrary to our hypothesis, Igf1r was 
upregulated in H19+/hIC1 livers. In placentas, Igf1r level was unchanged, consistent with 
no significant change in miR-675 expression in this tissue (Figure 2.12B). These data 
suggest that the miR-675 mediated silencing of Igf1r does not occur in liver or that other 
dominant molecular phenotypes caused by IC1 hypomethylation might be masking the 
silencing effect of miR-675.  
2.8 Testing the role of miR-675 vs H19 in growth regulation  
 Potentially distinct mechanisms used by H19 and miR-675 to suppress 
embryonic growth have not been investigated in a tissue-and/or temporal-specific 
manner. To address this, the H19+/hIC1 animals that exhibit increased H19 and miR-675 
expression and severe growth phenotype could serve as an informative platform (Figure 
2.13A). Therefore, we have designed two rescue experiments that would allow us to test 
the role of miR-675 independent of H19 in growth restriction caused by IC1 
hypomethylation (Figure 2.13B and C). This approach could shed light on the 
contribution of miR-675 and H19 in the etiology of SRS.  
2.8.1 H19+/miR-675mut x H19hIC1/+ 
H19miR-675mut allele 
First rescue experiment utilizes the mouse model, designated H19miR-675mut, 
generated by a previous member of the Bartolomei lab, Jennifer Kalish, MD, PhD. In this 
mouse model, the miR-675 sequence was mutated such that the stem-loop structure of 
the miR is maintained while the targeting ability is impaired. This mouse model does not 
seem to have any apparent phenotype thus far (personal communication with Jennifer 
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Kalish). Importantly, H19 expression is not affected in this model (Kalish et al., 
unpublished).  
Mating scheme 
The goal is to generate offspring from H19+/miR-675mut females and H19hIC1/+ males 
(Figure 2.13B). This will allow us to analyze the extent to which the reduced dosage of 
miR-675 has an effect in relieving the molecular and/or physiological phenotypes of the 
H19+/hIC1 animals. Thus, we will be able to elucidate the contribution of miR-675 in 
leading to the SRS-like phenotypes. These crosses have been setup and the E15.5 and 
E18.5 embryos and placentas will be collected.    
2.8.2 H19+/△H19 x H19hIC1/+ 
Generation of the H19△H19 allele 
 As a complementary approach, we generated a mouse model, designated 
H19△H19, in which the H19 sequence is deleted using the Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR)/Cas9 technology. To do this, two 
different pairs (pair A and B) of guide RNA (gRNA) were designed using the program 
developed by the laboratory of Dr. Feng Zhang (http://www.genome-
engineering.org/crispr/?page); within a pair of gRNA, each gRNA was designed to target 
the 5’ or the 3’ end of the H19 sequence (Figure 2.14A). The gRNAs were in vitro-
transcribed and injected with Cas9 mRNA (Trilink) directly into zygote stage embryos in 
B6 background. One pair of gRNA (either pair A or pair B) was injected per embryo. This 
approach led to in total ~26% efficiency in generating both female and male chimeras, 
with pair B exhibiting a higher efficiency (~24%) than pair A (~2%). Sequencing the 
deleted region revealed 2.7kb to 2.8kb deletion in the chimeras (Figure 2.14B). The 
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chimeras successfully transmitted the mutant allele through the germline. Both female 
and male mutant mice were fertile, and wild-type and mutant progeny were born in the 
expected Mendelian ratios with no sex bias. The mutant allele is currently maintained in 
B6 background via paternal transmission.          
Previous mouse models deleting the H19 sequence (Leighton et al., 1995b; 
Ripoche et al., 1997) left a transcription unit at the deleted site— NeoR cassette—that 
could potentially interfere with the imprinting mechanism at the locus. The other H19-
deletion mouse (Schmidt et al., 1999) left a loxP site at the locus. Importantly, the 
H19△H19 allele we generated does not introduce any exogenous sequence at the locus, 
eliminating the possibility of imprinting regulation being affected.    
Characterization of the H19+/△H19 and the H19△H19/+ animals 
Day 0 neonatal weight was analyzed in the maternal transmission (H19△H19/+) and 
the paternal transmission (H19+/△H19) animals. There was no significant weight difference 
between H19+/△H19 compared to wild-type siblings (H19+/+) (Figure 2.15A); yet, H19△H19/+ 
were significantly heavier compared to H19+/+ (i.e. H19△H19/+ displayed on average 13.8% 
increase in body weight compared to H19+/+) (Figure 2.15B). This result is similar to the 
observation made in the previous H19-deletion mouse models, where they noticed 4-
12% increase in body weight in day 3-5 neonates in various genetic backgrounds 
(Ripoche et al., 1997; Schmidt et al., 1999). Thus, our mouse model supports the role of 
H19 being a maternally expressed growth suppressor.  
Nevertheless, molecular analyses of these mice remain to be completed. Various 
tissues of the neonates were collected including brain, tongue, liver, kidney, and heart. 
Select tissues will be analyzed for parameters including allele-specific and total 
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expression of H19 and Igf2 and DNA methylation at IC1 to address the necessity of H19 
in the maintenance of imprinting at the H19/Igf2 locus. In addition, germ cells of these 
mice will be analyzed to address the effect of H19 deletion in methylation establishment 
at the IC1. 
Mating scheme 
 Similar to the approach proposed for the H19miR-675mut allele, the goal is to 
generate offspring from H19+/△H19 females and H19hIC1/+ males (Figure 2.13C). These 
crosses have been setup and the E15.5 and E18.5 embryos and placentas will be 
collected. This strategy will address the extent to which reducing the dosage of both H19 
and miR-675 alters the SRS-like phenotypes in the H19+/hIC1 animals.  
2.9 Discussion 
Using a mouse model replacing endogenous mIC1 with hIC1, we show that the 
ability of hIC1 to functionally replace mIC1 depends upon the parental origin of the hIC1 
allele.  
Maternally transmitted hIC1 properly carries out imprinting regulation at the 
endogenous mouse locus, suggesting that the IC1 imprinting on the maternal allele is 
largely conserved between mouse and human (Figure 2.16). Paternal transmission of 
hIC1, in contrast, leads to loss of H19 and Igf2 imprinting; H19 displays biallelic and 
increased expression and Igf2 is silenced (Figure 2.17). Offspring inheriting hIC1 
paternally also exhibit severe growth restriction. Other studies have shown that Igf2 null 
neonates are born smaller but viable (Baker et al., 1993; DeChiara et al., 1990), 
suggesting that prenatal lethality of H19+/hIC1 is not solely due to loss of Igf2. Notably, 
ectopic expression of H19 caused late-gestation lethality (Brunkow and Tilghman, 1991). 
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Thus, changes in both H19 and Igf2 may synergistically contribute to the severe growth 
restriction and prenatal lethality of H19+/hIC1.  
In addition to changes in H19 and Igf2, miR-675 and IGN gene levels are altered 
in H19+/hIC1 embryos and placentas (Figure 2.17). To our knowledge, this is the first 
report showing that complete biallelic insulation at the endogenous H19/Igf2 locus could 
lead to changes in miR-675 or other growth-regulating imprinted genes in vivo. Given 
that the maternally expressed imprinted genes tend to suppress growth, whereas 
paternally expressed imprinted genes promote growth, the seemingly disparate changes 
in IGN gene expression between H19+/hIC1 livers and placentas both encourage growth. 
This result reaffirms the previously proposed homeostatic role of IGN genes to control 
embryonic and placental growth. Despite these potentially compensatory changes, 
however, H19+/hIC1 embryos are still severely growth-restricted and die prenatally.  
Whether the increased level of miR-675 or H19 in H19+/hIC1 liver contributes to the 
embryonic growth restriction phenotype needs to be further investigated. We have setup 
experiments to specifically address this question as discussed in Chapter 2.8.1 and 
2.8.2. Surprisingly, miR-675 is only increased in livers, but not in placentas. It will be 
interesting to assess the expression of miR-675 later in gestation, such as E18.5-19.5, 
when the highest level of miR-675 is observed in both liver and placenta (Keniry et al., 
2012). However, it is possible that miR-675 is differently regulated in liver compared to 
placenta.  
The upregulation of Igf1r transcript, observed in a tissue where miR-675 was 
upregulated, is unexpected. This result does not invalidate Igf1r as a potential target of 
miR-675 in placenta (Keniry et al., 2012). Nevertheless, it is possible that the miR-675 
regulation of Igf1r is cell-type specific. Given that H19+/hIC1 tissues display changes in the 
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expression of Igf2 and other IGN genes, upregulation of the Igf1r transcript perhaps 
reflects a response to the altered IGF2-associated signaling pathway.  
Previous studies illustrated that abnormal H19 and Igf2 expression is linked to 
both placental and embryonic growth defects. Deletion of a placenta-specific Igf2 
transcript resulted in growth restriction of embryos in late gestation (Constância et al., 
2002). In a mouse model in which H19 is deleted and Igf2 expression is increased, both 
placenta and fetus are overgrown at E19 (Angiolini et al., 2011; Leighton et al., 1995b). 
In humans, placental growth defects are common among individuals with BWS and SRS 
(Armes et al., 2012; Yamazawa et al., 2008). We observed that H19+/hIC1 placentas are 
not only smaller but have abnormal placental morphology. While the contribution of an 
abnormal placenta to fetal growth defects is unclear, it is noteworthy that H19 is more 
highly expressed in labyrinthine zone compared to junctional zone (Keniry et al., 2012), 
and that Igf2 null mice display a disproportionate reduction of labyrinthine zone 
compared to junctional zone (Coan et al., 2008). These observations suggest a potential 
major growth-suppressing effect of increased H19 and silenced Igf2 expression in the 
labyrinthine zone.  
We also show that hIC1 is partially methylated in the male germline of H19hIC1/+ 
mice. This phenotype contrasts that of other mouse models that carry mIC1 mutations; 
in these mice, methylation is properly established at non-mutated CpGs in the male 
germline (Engel et al., 2004, 2006). This result suggests that interspecies 
communication between mouse and human in establishing IC1 methylation is ineffective. 
Based on our finding that hIC1 is abnormally enriched with activating H3K4me2 marks in 
the male germ cells, it is tempting to speculate that somatic histone modification marks 
carried from the maternal allele are not completely erased in the male germ cells (note 
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that hIC1 was necessarily transmitted maternally to generate offspring). Consequently, 
the establishment of DNA methylation at hIC1 is inhibited. This finding adds to the 
growing consensus that H3K4 methylation marks are inhibitory to de novo DNA 
methylation in the germline, whereas repressive histone marks do not play major role in 
methylation establishment at ICRs (Ciccone et al., 2009; Delaval et al., 2007; Lee et al., 
2010; Singh et al., 2013; Stewart et al., 2015). 
Finally, we show that the partially established methylation at hIC1 in the male 
germline is not properly maintained during preimplantation development. We also 
illustrate that CTCF ectopically binds to the hIC1 on the paternal allele in somatic cells. 
Similar results are described in a previous mouse model in which CpGs within the CTCF 
binding sites at the mIC1 were mutated to abrogate methylation, while retaining the 
CTCF-binding motifs intact. There, although methylation was properly established in the 
male germ cells at the mIC1, it was not maintained during preimplantation development 
(Engel et al., 2004). These data suggest that CTCF binding inhibits maintenance of DNA 
methylation in somatic cells, although the mechanism remains unknown. Alternatively, 
hIC1 might lack properties that allow the mouse imprint maintenance machinery to 
properly recognize the sequence. It is also possible that hIC1 contains inhibitory signals 
that block accessibility and/or activity of the mouse imprint maintenance machinery.  
2.10 Contributions 
 This chapter contains direct quotes and figures from Hur et al. published in 2016 
in Proceedings of the National Academy of Sciences (PNAS) (Hur et al., 2016). The 
target vector for the H19hIC1 mouse was made by a collaborative effort between Dr. 
Folami Ideraabdullah, a former member of the lab, currently at the University of North 
Carolina at Chapel Hill, and Andrea Freschi, currently in the laboratory of Dr. Andrea 
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Riccio at the Second University of Naples, Italy. Members of the laboratory of Dr. Shelley 
Berger at the time, including Dr. Lacey Luense and Ms. Angela Hines, performed the 
STA-PUT experiments. Dr. Catherine May in the laboratory of Dr. Klaus Kaestner 
provided guidance in generating the H19△H19 allele using the CRISPR/Cas9 technology. 
Dr. Joanne Thorvaldsen provided advice and guidance in performing experiments.  
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Figure 2.1 Comparison between mouse and human IC1. Mouse IC1 (top) has four CTSs and 
is ~2kb long. Human IC1 (bottom) has seven CTSs and is ~5kb long. Except for the CTCF-
binding motifs, overall sequence homology between the two IC1 is low (Jinno et al., 1996; Jones 
et al., 2002). The number of CpG sites and CpG density at IC1 are noted in the table. 
Approximate distance between H19 and IGF2 in both mouse and human are indicated. CTSs are 
numbered for convenience. Human and mouse drawings were adapted from Renfree et al. 
(Renfree et al., 2013). 
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Figure 2.2 Targeting strategy to generate the H19hIC1 allele. (A) Schematics of the 
endogenous locus, targeting vector (phIC1-neo), correctly targeted allele (H19hIC1-neo), and 
targeted allele after excision of the neoR cassette (H19hIC1). Depicted are the IC1 (white 
rectangle) with CTCF binding sites (black blocks within the IC1), H19 exons (gray rectangles), 
pBluescriptIIKS sequence (bold line), neoR cassettes (green rectangles), loxP sites (black 
arrowheads), and endogenous mouse DNA (thin line). Restriction sites and their relative positions 
(in kb) to the H19 transcription start sites are indicated above the endogenous locus. Probes (A, 
B, and C) used for Southern blot analyses are shown as thick lines below the endogenous locus. 
(B) Southern blot analysis to confirm correct targeting of the alleles. Genomic DNA from the wild-
type mouse (+/+), knock-in mouse before neoR excision (hIC1-neo/+), and knock-in mouse after 
neoR excision (hIC1/+) was either digested with EcoRV-MluI and hybridized to external 5’probe A 
or digested with StuI and hybridized to external 3’probe B or to internal probe C. (C) Depiction of 
mIC1 (top) and hIC1 (bottom) highlighting PCR analyzed regions (a-m). IC1s are illustrated in the 
orientation shown in Fig 2.2A, with each CTCF binding site (CTS) numbered. a: bisulfite 
treatment followed by sequencing for mIC1; b,c: chromatin immunoprecipitation followed by 
quantitative real-time PCR (ChIP-qRT-PCR) for mIC1; d: pyrosequencing for mIC1; e-h: bisulfite 
treatment followed by sequencing for hIC1; i-k: ChIP-qRT-PCR for hIC1; l: pyrosequencing for 
hIC1; m: bisulfite treatment followed by sequencing for hIC1 (used for oocytes).  
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Figure 2.3 Weight and expression analyses of maternal transmission of the H19hIC1 allele. 
(A) Neonatal (P0) weight of wildtype (+/+) and heterozygous (hIC1/+) mutant offspring. (B) Allele-
specific expression of H19 and Igf2 in neonatal liver analyzed by restriction fragment length 
polymorphism (RFLP). Genotypes (+/+ and hIC1/+) and maternal (m) and paternal (p) allele 
controls are indicated above each gel. (C) Total expression of H19 and Igf2 in neonatal liver 
analyzed by qRT-PCR. (A,C) Two-tailed Student's T-test with equal variance; no significant 
differences were observed. (A-C) +/+: n=11, hIC1/+: n=12 (from three litters). Bars represent the 
mean ± SEM; error bars in (A) are too small to be seen on the graph. 
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Figure 2.4 Methylation analyses of maternal transmission of the H19hIC1 allele. (A) Percent 
methylation at IC1 in neonatal liver measured by pyrosequencing. Maternal (m) and paternal (p) 
alleles in hIC1/+ are shown separately as different primers were used; assay d was used for the 
+/+ and hIC1/+(p); assay l was used for the hIC1/+(m) (Figure 2.2C). (B) Methylation levels of 
Kcnq1ot1, Peg1, Peg3, Snrpn, Dlk1/Gtl2 (IG-DMR) ICRs were measured by pyrosequencing in 
neonatal liver. (C) IC1 methylation in oocytes analyzed by bisulfite treatment followed by 
sequencing. Assay a was used for mIC1; assay m was used for hIC1 (Figure 2.2C). Empty and 
filled circles indicate unmethylated and methylated cytosines in CG dinucleotides, respectively. 
Each horizontal row of circles denotes individual strands of cloned DNA. Cytosines in CG 
dinucleotides that are conserved between mouse and human and located within CTS are 
depicted as black lines above the clones and marked as CTS 2 and 6 (Bell and Felsenfeld, 2000). 
(A,B) +/+: n=11, hIC1/+: n=12 (from three litters). (B) Two-tailed Student's T-test with equal 
variance; no significant differences were observed. Bars represent the mean ± SEM; error bars in 
(A) and (B) are too small to be seen on the graph.  
A 
B 
C 
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Figure 2.5 Weight and expression analyses of paternal transmission of the H19hIC1 allele. 
(A) E15.5 fetal and placental weight of wild-type (+/+) and heterozygous (+/hIC1) mutant offspring. 
(B) Fetal/placental weight ratio of E15.5 samples. Allele-specific expression of H19 and Igf2 in (C) 
E15.5 liver, (E) E15.5 placenta, and (G) E9.5 whole embryo analyzed by RFLP. PCR cycle 
numbers varied between +/+ and +/hIC1 for Igf2 (see Table 5.1). Total expression of H19 and 
Igf2 in (D) E15.5 liver, (F) E15.5 placenta, and (H) E9.5 whole embryo analyzed by qRT-PCR. 
Two-tailed Student's T-test with (A) equal variance and (D,F,H) unequal variance; ** (P < 0.01); 
*** (P < 0.001); **** (P < 0.0001). (A,B,D,F) +/+: n=8, +/hIC1: n=6 (from two litters). (H) +/+: n=5, 
+/hIC1: n=7 (from two litters). Bars represent the mean ± SEM; error bars in (D,F,H) are too small 
to be seen on the graph. 
A B 
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Figure 2.6 Methylation analyses of paternal transmission of the H19hIC1 allele. Percent 
methylation at IC1 in (A) E15.5 liver and (B) E15.5 placenta measured by pyrosequencing; assay 
d was used for the +/+ and +/hIC1(m); assay l was used for the +/hIC1(p) (Figure 2.2C). (C) 
Methylation levels of Kcnq1ot1, Peg1, Peg3, Snrpn, Dlk1/Gtl2 (IG-DMR) ICRs were measured by 
pyrosequencing in E15.5 liver. (A,B,C) +/+: n=8, +/hIC1: n=6 (from two litters). Error bars in (A-C) 
are too small to be seen on the graph. (C) Two-tailed Student's T-test with equal variance; no 
significant differences were observed. Bars represent the mean ± SEM. (A,B,C) error bars are too 
small to be seen on the graph. 
A B IC1 IC1 
C 
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Figure 2.7 CTCF-binding analyses of paternal transmission of the H19hIC1 allele. CTCF 
binding at mIC1 and hIC1 in heterozygous (hIC1/+ and +/hIC1) E12.5 MEFs analyzed by ChIP-
qRT-PCR; assays b, c, i, k were used (Figure 2.2C); results from two biological replicates are 
shown separately; y-axis denotes percent input of CTCF IP normalized to non-specific IgG 
(percent input CTCF - percent input IgG). 
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Figure 2.8 Methylation at IC1 in H19+/hIC1 embryos during development. Bar graphs 
summarize the DNA methylation status of E9.5 whole embryo (+/+: n=5, +/hIC1: n=7, two litters), 
E6.5 whole embryo (+/+: n=5, +/hIC1: n=7, two litters), and blastocysts (+/+: n=6, +/hIC1: n=9, 
four litters) measured by pyrosequencing. Assay d was used for the +/+ and +/hIC1(m) and assay 
l was used for the +/hIC1(p) (Figure 2.2C). On the right, methylation at hIC1 was analyzed by 
bisulfite treatment followed by sequencing in one representative +/hIC1 sample from each 
developmental stage; assays e-h were used (Figure 2.2C). Cytosines in CG dinucleotides that 
are conserved between mouse and human and located within CTS are depicted as black lines 
above the clones and marked as CTS 1,2,3,4, and 6 (Bell and Felsenfeld, 2000). Cytosines 
measured by pyrosequencing are marked with an asterisk. Bars represent the mean ± SEM. 
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Figure 2.9 Incomplete establishment of imprinting at the hIC1 in knock-in male germ cells. 
(A) Percent methylation at IC1 measured by pyrosequencing; assays d and l were used (Figure 
2.2C). From left to right, results at the endogenous hIC1 in mature sperm samples from fertile 
men (hSP1, hSP2), at the endogenous mIC1 and the targeted hIC1 in knock-in sperm (KISP) 
from adult mice, and at the targeted hIC1 in pools of H19+/hIC1 two-cell stage embryos (KI2-cell) 
are shown. KISP: n=6 mice, KI2-cell pools: n=3. Two-tailed Student's T-test with equal variance; * 
(P<0.05). Bars represent the mean ± SEM; error bar of the KISP(mIC1) is too small to be seen on 
the graph. (B) Methylation at hIC1 in KISP and hSP1 analyzed by bisulfite treatment followed by 
sequencing; assays e-h are used (Figure 2.2C). Cytosines in CG dinucleotides that are 
conserved between mouse and human and located within CTS are depicted as black lines above 
the clones and marked as CTS 1,2,3,4, and 6 (Bell and Felsenfeld, 2000). Cytosines measured 
by pyrosequencing are marked with an asterisk. (C) ChIP-qRT-PCR for H3K4me2 and H3K9me3 
at the mIC1 and hIC1 in knock-in round spermatids; assays b and j were used (Figure 2.2C). Two 
independent pools of round spermatids were generated as detailed in Chapter 5.6, and the 
results from each pool are shown separately. Y-axis denotes the ChIP signal of each histone 
mark normalized to that of total H3 (e.g. percent input H3K4me2/percent input total H3). 
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Figure 2.10 Changes in levels of imprinted gene network (IGN) genes in H19+/hIC1 embryos 
and placentas. For the y-axis, the mean value of +/+ is arbitrarily set as 1. (A,B) +/+: n=8, 
+/hIC1: n=6 (from two litters). White bars: +/+, black bars: +/hIC1. P-value was calculated using 
two-tailed Student's T-test with equal variance; * (P < 0.05); *** (P < 0.001). Bars represent the 
mean ± SEM.  
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Figure 2.11 Analyses of H19+/hIC1 placentas. (A) Representative cross-sections of E15.5 +/+ 
and +/hIC1 placentas stained with haematoxylin and eosin. Black lines outline the decidua (DC), 
junctional zone (JZ), and labyrinthine zone (Lab). Scale bar represents 1000μm. (B) Stereological 
analysis of the junctional zone (JZ) area to labyrinth zone (Lab) area ratio in E15.5 +/+ and 
+/hIC1 placentas. (B) +/+: n=5, +/hIC1: n=4 (from one litter). Two-tailed Student's T-test with 
equal variance; ** (P<0.01). Bars represent the mean ± SEM. 
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Figure 2.12 Analyses of miR-675 and Igf1r in H19+/hIC1 embryos and placentas. (A) Total 
expression of miR-675-3p and miR-675-5p in E15.5 livers and placentas, normalized to the level 
of snoRNA202. (B) Total expression of Igf1r in E15.5 livers and placentas. (A,B) +/+: n=8, +/KI: 
n=6 (from two litters). White bars: +/+, black bars: +/hIC1. (A,B) P-value was calculated using 
two-tailed Student's T-test with equal variance; * (P < 0.05); **** (P < 0.0001).  Bars represent the 
mean ± SEM.  
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Figure 2.13 Strategies to address the specific role of miR-675 and H19 in growth regulation. 
(A) Top, H19/Igf2 regulation in the wild-type (H19+/+). Bottom, H19/Igf2 regulation upon paternal 
transmission of the H19hIC1 allele (H19+/hIC1). (B) A schematic of a cross between H19+/miR-675mut 
female and H19hIC1/+ male. (C) A schematic of a cross between H19+/ΔH19 female and H19hIC1/+ 
male. (B,C) Mutant or deletion alleles are indicated with striped boxes. The parent-of-origin of the 
allele is indicated with a female(♀) or male (♂) symbol.  
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Figure 2.14 CRISPR/Cas9 gRNA designs for deleting the H19 sequence. (A) Shown is the 
endogenous mouse H19 (~2.5kb) sequence that is composed of five exons (E). Two pairs of 
gRNA were designed: pair A (5A gRNA-3A gRNA) and pair B (5B gRNA-3B gRNA). Either pair A 
or pair B was injected into zygote stage embryos. A set of primer (H19-214 and H19+2722) that 
was used to genotype the deletion allele is indicated in pink. (B) A representative genotyping gel 
of chimeras. Injection of either pair A or pair B generated chimeras with correct deletions. When 
the H19 sequence is successfully deleted, the H19-214 and H19+2722 primer set amplifies ~200-
250bp fragments (size may vary depending on the indels generated). The amplified fragments 
were gel-isolated and sequenced to confirm the deletions. Left most lane: 1kb+ ladder 
(Invitrogen); lanes indicated with yellow asterisks: deletion alleles, otherwise: wild-type alleles. 
The non-specific PCR band is indicated. 
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Figure 2.15 day 0 neonatal weight analyses of the H19ΔH19 allele. (A) Paternal transmission of 
the H19ΔH19 allele. +/+: n=6, +/△H19: n=8 (from two litters). (B) Maternal transmission of the 
H19ΔH19 allele. +/+: n=10, △H19/+: n=10 (from three litters). (A,B) At least two different chimeric 
founders (i.e. founder with different length of deletion) were used to generate litters. Each dot or 
square on the graph represents individual pup. P-value was calculated using two-tailed Student's 
T-test with equal variance; *** (P < 0.001), otherwise, not significant.  
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Figure 2.16 Model for maternal transmission of the H19hIC1 allele. During the female germ cell 
development, both hIC1 and mIC1 are properly hypomethylated. Once an egg carrying hIC1 is 
fertilized with a sperm carrying mIC1 and develops into hIC1/+ somatic cells, the CTCF-
dependent insulator is properly formed on the maternal hIC1. This leads to the correct imprinted 
expression of the H19/Igf2 locus. The parent-of-origin of the allele is indicated with a female(♀) or 
male (♂) symbol.   
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Figure 2.17 Model for paternal transmission of the H19hIC1 allele. During male germ cell 
development, unlike mIC1, hIC1 is unusually enriched with H3K4me2, which is inhibitory to the de 
novo DNA methyltransferase machinery. This leaves some regions of hIC1 (that are enriched 
with H3K4me2) hypomethylated. Once a sperm carrying hIC1 fertilizes an egg carrying mIC1 and 
develops into a zygote, CTCF binds to the unmethylated CTCF-binding sites at the hIC1. As the 
zygote undergoes cell division and develops into +/hIC1 somatic cells, the partially established 
methylation marks at hIC1 are not maintained, leading to a fully hypomethylated state of hIC1. 
Ultimately, biallelic insulation at the locus is established, resulting in loss of imprinting. The 
parent-of-origin of the allele is indicated with a female(♀) or male (♂) symbol. 
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CHAPTER 3.                                    
PATIENT-DERIVED HUMAN CELL BASED MODEL 
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3.1 Background and study rationale  
Patient samples expand our knowledge in imprinting. Investigating various 
human mutations associated with imprinting disorders can provide additional insights 
into how imprinting is regulated in human, which can be translated into therapeutic 
strategies. Importantly, understanding mechanisms underlying mutations such as 
pUPD11, that are harder to engineer in other model systems, can tremendously benefit 
from analyzing the patient samples. However, these resources have limitations. First, 
mosaicism is prevalent among BWS population: pUPD11 patients are mosaic for the 
genetic mutations (Kalish et al., 2014), and individuals with IC1 microdeletions or OCT4-
binding mutations carry mosaic epimutations (Beygo et al., 2013; Demars et al., 2010; 
Habib et al., 2014; Poole et al., 2012; Prawitt et al., 2005; Sparago et al., 2004). The 
mosaic background of an individual can obscure the extent to which the specific 
genetic/epigenetic mutation is sufficient to drive the phenotype of the patient. Second, 
easily accessible yet disease non-relevant tissues, such as fibroblasts and blood, are not 
the ideal surrogates to investigate the disease etiology. Thus, developing patient-derived 
models that are devoid of mosaicism in the context of the disease-relevant cell types is 
necessary.  
iPSC technology allows derivation of clonal cell lines, where each cell line has a 
uniform genetic and epigenetic background. Subsequently, these cell lines can be 
differentiated into cell type of interest (Unternaehrer and Daley, 2011). These merits of 
iPSC technology have led various common and rare disorders to be modeled in vitro, 
including imprinting disorders such as Angelman syndrome and Prader-Willi syndrome 
(Chamberlain et al., 2010; Cruvinel et al., 2014; Stelzer et al., 2014).   
Previous reports have suggested a link between the imprinted genes and 
pluripotency of stem cells, although no concrete consensus has been reached (Chang et 
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al., 2014; Stadtfeld et al., 2010, 2012). The correct imprinted status of the DLK1-DIO3 
locus (Figure 3.1) has received a wide attention as a molecular marker for assessing the 
quality of stem cells (Benetatos et al., 2014). Hypermethylation and/or aberrant silencing 
of the maternally expressed long non-coding RNAs and microRNAs at the DLK1-DIO3 
locus have been linked to poor developmental potential of mouse iPSCs (Stadtfeld et al., 
2010; Stadtfeld et al., 2012), suboptimal pluripotency in mouse ESCs (Liu et al., 2010), 
and inefficient neural lineage differentiation potential of human ESCs (Mo et al., 2015).   
In contrast, Christodoulou et al. showed that mouse iPSCs with hypermethylated 
Dlk1-Dio3 locus had similar differentiation capacity into definitive endoderm compared to 
mouse ESCs with normal Dlk1-Dio3 methylation (Christodoulou et al., 2011). Chang et 
al. noted that hypomethylation of the Zrsr1 imprinted gene, but not hypermethylation of 
the Dlk1-Dio3 locus, is correlated with poor quality of mouse iPSCs (Chang et al., 2014). 
Thus, the extent to which the DLK1-DIO3 locus hypermethylation affects iPSC quality 
requires further investigation. 
 Other ICRs have infrequently exhibited stochastic aberrant DNA methylation in 
both mouse and human pluripotent stem cells (Nazor et al., 2012; Nishino et al., 2011; 
Sun et al., 2012; Takikawa et al., 2013). Overall, these studies emphasize the need for 
careful examination of the stability of imprinted genes in the pluripotent stem cells. Such 
inspection is especially crucial for the cell lines that will be used for therapeutic or 
disease-modeling of imprinting disorders. 
Here, we present derivation of the iPSCs from pUPD11 BWS patient fibroblasts 
(Figure 3.2). We show that genetically-matched pUPD11 and non-pUPD11 iPSCs can 
be derived from mosaic samples. We primarily analyzed DNA methylation at various 
imprinted regions in our cell lines, and show that while other regions exhibit proper 
methylation profile, the DLK1-DIO3 locus is aberrantly methylated. Although the 
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significance underlying this molecular phenomenon remains to be determined, the 
derived cell lines are useful resources that can be further differentiated into clinically-
relevant endodermal and mesodermal lineages to examine molecular mechanisms 
leading to BWS.   
3.2 Derivation of iPSCs from mosaic pUPD11 fibroblasts 
Skin samples from four male patients were collected during surgical procedures 
and used to generate fibroblast cell lines. pUPD11 breakpoints as well as extent of 
mosaicism of pUPD11 for all patients were determined using genome-wide single-
nucleotide polymorphism (SNP) microarray analysis (Figure 3.3 and data not shown). To 
demonstrate that two populations of cells, designated isogenic pUPD11 and non-
pUPD11 iPSCs, can be derived from mosaic fibroblast cell lines, we reprogrammed 
fibroblasts from these patients using either polycistronic STEMCCA lentivirus (Sommer 
et al., 2009) or episomal plasmids (Okita et al., 2011). As a sex- and cell-type- matched 
control, we reprogrammed one male fibroblast cell line (IMR91) using episomal plasmids 
(Figure 3.3). Most of the iPSC-like colonies were isolated, and the clones that thrived for 
at least three passages were counted and noted in Figure 3.3. All fibroblast cell lines and 
representative iPSC lines had a normal karyotype (data not shown). The iPSCs 
expressed similar levels of pluripotency markers and all three embryonic germ layer 
markers upon differentiation into embryoid bodies (EBs) as measured by qRT-PCR and 
immunofluorescence (Figure 3.4, 3.5A, and 3.5B), regardless of the reprogramming 
strategy or the extent of pUPD11 in the parental fibroblasts. To determine which iPSCs 
had pUPD11 versus biparental chromosome 11, we used microsatellite fragment 
analyses or restriction fragment length polymorphisms (Table 5.4). Notably, the percent 
of pUPD11 iPSC clones derived relative to the total number of iPSC clones was 
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reflective of the percent pUPD11 in the initial fibroblasts (Figure 3.3). We did not obtain 
any pUPD11 iPSCs from patient 2 fibroblasts (Figure 3.3), likely due to the low level of 
pUPD11 in the initial fibroblasts. These results demonstrate that pUPD11 and non-
pUPD11 iPSCs can be derived from a mosaic patient fibroblast sample. 
3.3 Analyses of the pUPD11-relevant ICRs and imprinted genes 
DNA methylation status at IC1 and IC2 is the most widely used molecular marker 
to diagnose BWS (Mussa et al., 2016). Thus, it is essential that iPSCs derived to model 
BWS display normal and intact methylation profile at both ICRs. To determine that 
pUPD11 and non-pUPD11 iPSCs reflect the DNA methylation status of the parental 
fibroblasts, IC1 and IC2 methylation levels were measured. For IC1 methylation 
analyses, we performed pyrosequencing for patient 1 and 2 cell lines. Due to the 
presence of SNPs in the pyrosequencing primer binding site for patient 3 and 4 cell lines, 
combined bisulfite restriction analysis (COBRA) was used. IC2 methylation for all patient 
lines was analyzed using COBRA. Because pUPD11 iPSCs have two copies of the 
paternal contribution of the IC1 (Figure 1.8), they exhibited ~100% methylation as 
expected, and non-pUPD11 iPSCs displayed the expected ~50% methylation (Figure 
3.6A). To validate the COBRA results, IC1 methylation in the patient 3 and 4 fibroblast 
cell lines and select non-pUPD11 and pUPD11 iPSCs was determined using bisulfite 
treatment followed by direct sequencing. The sequencing results replicated the COBRA 
results (Figure 3.6B). Because the paternally inherited IC2 is normally unmethylated, as 
expected, all pUPD11 iPSCs analyzed showed no detectable methylation at IC2 (Figure 
3.7), whereas non-pUPD11 iPSCs showed normal methylation. Therefore, IC1 and IC2 
methylation status is appropriate for the parent-of-origin and is maintained after the 
derivation and culture of iPSCs.  
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To investigate whether DNA methylation is stably maintained across multiple 
passages, select patient 1 and 2 iPSCs were cultured over prolonged periods. All iPSCs 
maintained stable IC1 methylation pattern in later passages (Figure 3.8), demonstrating 
that the reprogramming and/or culture conditions for iPSCs does not perturb IC1 
methylation in our study. 
Next, we evaluated expression of imprinted genes in the pUPD11 region. 
Because H19 and Igf2 are lowly expressed in the mouse blastocysts (Lee et al., 1990; 
Poirier et al., 1991), we did not expect to observe high levels of expression of these 
genes in iPSCs. Consistently, expression of both genes was low in iPSCs. Therefore, we 
differentiated iPSCs into EBs to examine H19 and IGF2 RNA levels. pUPD11 EBs 
displayed no expression of H19, whereas non-pUPD11 EBs expressed H19. 
Furthermore, pUPD11 EBs expressed higher levels of IGF2 compared to the non-
pUPD11 EBs (Figure 3.9). These results demonstrate that H19 and IGF2 mRNA in EBs 
appropriately reflect their non-pUPD11 versus pUPD11 statuses of their counterpart 
iPSCs.     
3.4 Analyses of DNA methylation at other ICRs  
We also analyzed imprinted loci outside of the pUPD11 region. First, we 
analyzed DNA methylation at the SNRPN ICR, implicated in Prader-Willi syndrome 
(Cassidy et al., 2012) using pyrosequencing. All iPSCs showed normal methylation 
levels at the SNRPN ICR similar to the level detected in the parental fibroblasts (Figure 
3.10). Hence, reprogramming strategies employed in the current study lead to stable 
methylation status at the SNRPN ICR. 
Next, we examined the DLK1-DIO3 locus using pyrosequencing. Here, we 
analyzed two DMRs—the intergenic differentially methylated region (IG-DMR), which 
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serves as the locus ICR, and the MEG3-DMR, a paternally methylated sequence that 
reflects the MEG3 imprinted expression (Figure 3.1) (Benetatos et al., 2014). Consistent 
with previous reports, many iPSC clones were abnormally hypermethylated at the DLK1-
DIO3 locus, in contrast to their initial parental fibroblasts, which were normally 
methylated (Figure 3.11A). To address whether prolonged culture had additional effects 
on DNA methylation stability at the locus, select patient 1 and 2 iPSCs were cultured 
over prolonged periods. Some clones (i.e. patient 1 clone 43, patient 2 clones 68 and 
76) became hypermethylated over extended culture at one or both DMRs (Figure 3.11B), 
suggesting that aberrant methylation can manifest during prolonged culture. We also 
observed that different aliquots of the same iPSC line thawed independently exhibited 
variable DNA methylation patterns (data not shown). Nevertheless, some clones (i.e. 
patient 1 clone 9 and patient 2 clone 61) maintained normal methylation for 7-10 
passages (Figure 3.11B). Overall, these results suggest that the DLK1-DIO3 locus is 
especially sensitive to DNA methylation perturbation during iPSC reprogramming and/or 
culture. 
3.5 The effect of vitamin C in ICR methylation 
Several groups have advocated the use of vitamin C (VC) supplementation 
during iPSC reprogramming for enhancing the efficiency of reprogramming and/or 
generating high-quality mouse and human iPSCs (Chen et al., 2013; Esteban et al., 
2010; Stadtfeld et al., 2012; Xu et al., 2015). To this end, we reprogrammed the IMR91 
fibroblast cell line with (+VC) or without VC (-VC) in parallel experiments; 18+VC and 17-
VC IMR91 iPSC clones were isolated (Figure 3.3). The efficiency of expanding viable 
clones was the same regardless of VC exposure. IC1, IC2, and SNRPN ICR maintained 
normal methylation levels in the IMR91 iPSCs regardless of VC treatment (Figure 3.12A 
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and B). Interestingly, we noticed that VC leads to an initial, average, lower methylation 
level at both IG-DMR and MEG3-DMR in iPSCs (Figure 3.13A). All clones examined, 
however, became hypermethylated at IG-DMR and MEG3-DMR in later passages, 
irrespective of the VC treatment (Figure 3.13B). 
3.4 Discussion 
In this study, we report the establishment of iPSC models of BWS. We derived 
both pUPD11 and non-pUPD11 iPSCs from three BWS patient fibroblast cell lines that 
have distinct pUPD11 regions and differing levels of mosaicism for pUPD11 in the 
parental fibroblasts. In each reprogramming experiment, the non-pUPD11 iPSCs serve 
as internal controls for pUPD11 iPSCs, as the cell lines are isogenic except for the 
pUPD11 regions. The use of matched iPSCs to study human diseases diminishes 
potential background effects caused by genetic variations between individuals. To our 
knowledge, these lines are the first iPSC models of BWS, thus a valuable tool to study 
the mechanisms of IC1 and IC2 imprinting in BWS.  
  Importantly, we showed that the proportion of the pUPD11 iPSC lines relative to 
the total iPSC lines reflects the percent of pUPD11 cells in the patient fibroblasts. These 
results suggest that during reprogramming, the pUPD11 cells do not have growth 
advantages, even though the growth-promoting gene, IGF2, is overrepresented and the 
growth-suppressing genes, CDKN1C and H19 are repressed in these cells. Lack of a 
growth advantage is likely due to relatively low expression of the genes during the 
reprogramming process and propagation of iPSCs, as we showed that H19 and IGF2 
expression is low in the iPSCs yet increased upon differentiation into EBs. Similarly, 
CDKN1C is significantly upregulated upon human ESCs differentiation into EBs 
(Bhattacharya et al., 2005). 
77 
 
We examined DNA methylation at five DMRs in the iPSCs: IC1, IC2, SNRPN ICR, 
IG-DMR, and MEG3-DMR, and showed that methylation was properly maintained at IC1, 
IC2 and SNRPN ICR. However, we observed a prevalence of hypermethylation at the 
DLK1-DIO3 locus in the iPSCs, as reported by others (Benetatos et al., 2014). To what 
extent the DLK1-DIO3 locus hypermethylation affects human iPSC quality remains 
unclear. Mo et al. inferred that hypermethylation at the DLK1-DIO3 locus results in 
inefficient ectodermal differentiation (Mo et al., 2015). However, EB samples 
differentiated from the non-pUPD11 and pUPD11 iPSCs with hypermethylated DLK1-
DIO3 locus expressed similar levels of the ectodermal markers compared to the EB 
sample (patient 1, pUPD11 clone 9) differentiated from the iPSCs with a normal DLK1-
DIO3 methylation. The discrepancy between the two studies may be attributed to the 
different cell sources (human ESCs vs iPSCs) and culture techniques. Nevertheless, 
appropriate expression of germ lineage markers in all EBs analyzed suggests that our 
iPSCs have normal differentiation potential into all three germ lineages independent of 
the methylation status at the DLK1-DIOS locus.  
We showed that the VC supplementation during iPSC reprogramming was 
associated with a significantly lower methylation level at the DLK1-DIO3 locus in the 
early passage iPSCs compared to the iPSCs derived without VC supplementation, 
consistent with the results obtained by Stadtfeld et al. where addition of VC during 
reprogramming suppressed hypermethylation at the Dlk1-Dio3 locus in mouse iPSCs 
(Stadtfeld et al., 2012). However, in our study, the iPSCs in the +VC group became 
hypermethylated over extended culture. Whether the mouse iPSCs with normal Dlk1-
Dio3 methylation in the study by Stadtfeld et al. maintained their methylation over 
extended culture is unclear. However, it is possible that VC affects the mouse and 
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human DLK1-DIO3 locus differently, through its influence on multiple epigenetic 
regulators such as histone demethylases and DNA demethylases (Blaschke et al., 2013; 
Chen et al., 2013; Eid and Abdel-Rehim, 2016; Gao et al., 2015; Shi et al., 2010; Wang 
et al., 2011). 
3.5 Contributions 
The work described in this chapter is a collaborative effort. Dr. Jennifer Kalish 
collected the patient samples, performed SNP array, and provided general advice for the 
project. Dr. Montserrat Anguera provided pivotal guidance in deriving and characterizing 
iPSCs. Dr. Joanne Thorvaldsen performed iPSC reprogramming. Dr. Dong Hun Woo, 
currently at the NEXEL Co., Ltd, Seoul, Korea, provided STEMCCA lentivirus. Suhee 
Chang, from the laboratory of Dr. Marisa Bartolomei, Carolyn Lye, currently at the Yale 
medical school, and Alice Yu, from the laboratory of Dr. Jennifer Kalish, assisted in 
various aspects of iPSC characterization. Dr. Joanne Thorvaldsen and Suhee Chang 
have significantly contributed in expanding and analyzing iPSCs.  
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Figure 3.1 DLK1-DIO3 imprinted locus in human 14q32. On the maternal allele (♀), lncRNA 
MEG3 as well as a large cluster of miRNAs and snoRNA are active. On the paternal allele (♂), 
protein-coding genes including DLK1, RTL1, and DIO3 are expressed. The IG-DMR serves as 
the ICR for the locus, and DNA methylation at the MEG3-DMR is established in the somatic cells. 
Both IG-DMR and MEG3-DMR are methylated on the paternal allele. Centromeric (C) and 
telomeric (T) ends are indicated. Not drawn to scale. 
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Figure 3.2 A schematic of pUPD11 fibroblasts reprogramming. Mosaic pUPD11 fibroblasts 
consist of both non-pUPD11 (represented in grey) and pUPD11 (represented in pink) cells. When 
these fibroblasts are reprogrammed using the four Yamanaka factors (OCT4, KLF4, SOX2, C-
MYC) (Takahashi and Yamanaka, 2006), cell lines that are purely non-pUPD11 or pUPD11 are 
derived. These iPSCs can be differentiated into lineage of interest, such as endoderm or 
mesoderm.  
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Figure 3.3 Summary of iPSC reprogramming in this study. A schematic illustrating 
chromosome 11 with relative locations of IC1 and IC2 as well as regions of pUPD11 (colored 
retangles) of each pUPD11 fibroblast cell line (Patient 1, 2, 3, 4). pUPD11 break points are 
indicated next to regions of pUPD11 (Human Genome Build 37, hg19, 2009). Percent pUPD11 in 
the parental fibroblasts, methods of reprogramming, use of vitamin C during reprogramming, and 
numbers of total, non-pUPD11, and pUPD11 iPSC clones derived, of four pUPD11 fibroblast cell 
lines and one control fibroblast cell line (IMR91) are summarized. NA: not applicable.  
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Figure 3.4 Phase-contrast and immunofluorescence images of human iPSCs. Expression of 
pluripotency markers (SSEA3, SSEA4, TRA1-60, TRA1-81 and OCT4) in select iPSC clones. 
SSEA1 was used as a negative control cell surface marker for iPSCs. Scale bars, 100𝜇m. 
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Figure 3.5 Expression of pluripotency markers in iPSCs and expression of germ lineage 
markers, H19, and IGF2 in EBs. (A) Expression of pluripotency markers in the iPSCs was 
measured by qRT-PCR. Expression in the iPSCs were normalized to expression in the respective 
parental fibroblasts (set to 1). Fib: fibroblasts. (B) Expression of germ lineage markers in the EBs 
measured by qRT-PCR. Endoderm markers: AFP and GATA4; mesoderm markers: HAND1 and 
RUNX2; ectoderm markers: NACM1 and FGF5. Expression in the EBs were normalized to 
expression in the counterpart iPSCs (set to 1). (A,B) Labels on X-axis denote patient 
number/IMR91 followed by clone number (i.e. 1_5: patient 1 clone 5, IMR91_37: IMR91 clone 37). 
Y-axis is in log base 10 scale. pUPD11 clones are highlighted in grey boxes; otherwise, non-
pUPD11.  
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Figure 3.6 Methylation at IC1 in iPSCs and fibroblasts. (A) Methylation at IC1 was measured 
by pyrosequencing (in patient 1 and 2 cell lines) and COBRA (in patient 3 and 4 cell lines). Each 
graph includes results from the parental fibroblast cell line (dotted bar) and hiPSCs derived from 
the respective fibroblast cell line (solid bars). Labels on X-axis denote clone number followed by 
passage number (i.e. 1p9: clone number 1 at passage 9). pUPD11 clones are highlighted in grey 
boxes; otherwise, non-pUPD11. (B) IC1 methylation of patient 3 and 4 fibroblasts and iPSCs 
measured by bisulfite treatment followed by direct sequencing. 
A 
B 
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Figure 3.7 Methylation at IC2 in iPSCs and fibroblasts. All samples were analyzed by COBRA. 
Bars for the pUPD11 iPSCs are too small to be seen on the graph. Each graph includes results 
from the parental fibroblast cell line (dotted bar) and hiPSCs derived from the respective fibroblast 
cell line (solid bars). Labels on X-axis denote clone number followed by passage number (i.e. 
1p9: clone number 1 at passage 9). pUPD11 clones are highlighted in grey boxes; otherwise, 
non-pUPD11. 
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Figure 3.8 Methylation at IC1 in select patient 1 and 2 iPSCs during extended culture. Bars 
are grouped by clones. Each graph includes results from the parental fibroblast cell line (dotted 
bar) and hiPSCs derived from the respective fibroblast cell line (solid bars). Labels on X-axis 
denote clone number followed by passage number (i.e. 1p9: clone number 1 at passage 9). 
pUPD11 clones are highlighted in grey boxes; otherwise, non-pUPD11. 
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Figure 3.9 Expression of H19 and IGF2 in iPSCs and EBs measured by qRT-PCR. H19 
expression (left graph) in the iPSCs are indicated in light red bars and EBs in dark red bars. IGF2 
expression (right graph) in the iPSCs are indicated in light blue bars and EBs in dark blue bars. 
Note scale breaks on the y-axes for both graphs. Bars for the pUPD11 clones as well as some 
iPSCs on the left graph are too small to be seen. Some bars for the iPSCs on the right graph are 
too small to be seen. Labels on X-axis denote patient number/IMR91 followed by clone number 
(i.e. 1_5: patient 1 clone 5, IMR91_37: IMR91 clone 37). pUPD11 clones are highlighted in grey 
boxes; otherwise, non-pUPD11. 
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Figure 3.10 Methylation at SNRPN ICR in iPSCs and fibroblasts. All samples were analyzed 
by pyrosequencing. Each graph includes results from the parental fibroblast cell line (dotted bar) 
and hiPSCs derived from the respective fibroblast cell line (solid bars). Labels on X-axis denote 
clone number followed by passage number (i.e. 1p9: clone number 1 at passage 9). pUPD11 
clones are highlighted in grey boxes; otherwise, non-pUPD11. 
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Figure 3.11 Methylation at IG-DMR and MEG3-DMR in iPSCs and fibroblasts. Methylation at 
IG-DMR and MEG3-DMR were analyzed by pyrosequencing. (A) Methylatoin at IG-DMR and 
MEG3-DMR in all patient cell ilnes (B) Methylation at IG-DMR and MEG3-DMR in select patient 1 
and 2 iPSCs during extended culture. Bars are grouped by clones. (A,B) pUPD11 clones are 
highlighted in grey boxes; otherwise, non-pUPD11. Methylation at IG-DMR is indicated in dark 
blue bars and MEG3-DMR in light blue bars. Each graph includes results from the parental 
fibroblast cell line (dotted bar) and hiPSCs derived from the respective fibroblast cell line (solid 
bars). Labels on X-axis denote clone number followed by passage number (i.e. 1p9: clone 
number 1 at passage 9). pUPD11 clones are highlighted in grey boxes; otherwise, non-pUPD11. 
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Figure 3.12 IC1, IC2, and SNRPN ICR methylation in IMR91 iPSCs derived from +VC or -VC 
reprogramming. (A) Methylation at IC1 was measured by pyrosequencing. ns, not significant; 
two-tailed student’s t test with unequal variance. (B) Methylation at IC2 and SNRPN ICR was  
measured by COBRA and pyrosequencing, respectively. (A,B) iPSCs derived from +VC 
reprogramming are highlighted in yellow boxes; otherwise, derived from -VC reprogramming. 
Each graph includes results from the parental fibroblast cell line (dotted bar) and hiPSCs derived 
from the respective fibroblast cell line (solid bars). Labels on X-axis denote clone number 
followed by passage number (i.e. 1p9: clone number 1 at passage 9).  
 
 
 
A 
B 
91 
 
 
 
 
Figure 3.13 DLK1-DIO3 locus methylation in IMR91 iPSCs derived from +VC or -VC 
reprogramming. (A) Methylation at IG-DMR and MEG3-DMR was measured by pyrosequencing. 
**, p<0.01; two-tailed student’s t test with unequal variance. (B) Methylation at IG-DMR and 
MEG3-DMR in select iPSCs during extended culture. Bars are grouped by clones. (A,B) iPSCs 
derived from +VC reprogramming are highlighted in yellow boxes; otherwise, derived from -VC 
reprogramming. Methylation at IG-DMR is indicated in dark blue bars and MEG3-DMR in light 
blue bars. Each graph includes results from the parental fibroblast cell line (dotted bar) and 
hiPSCs derived from the respective fibroblast cell line (solid bars). Labels on X-axis denote clone 
number followed by passage number (i.e. 1p9: clone number 1 at passage 9). 
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CHAPTER 4.                                                                      
FUTURE DIRECTIONS 
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4.1 Humanized mouse model  
Disease modeling of BWS 
IC1 alterations associated with BWS manifest clinical phenotypes when the 
mutant allele is maternal in origin (Figure 1.7). It is thought that the disrupted insulator 
function of IC1 on the maternal allele leads to biallelic expression of IGF2 and reduced 
H19 expression, contributing to the overgrowth phenotype. Interestingly, however, these 
alterations exhibit mosaic gain of methylation at IC1, suggesting that not all cells are 
aberrantly DNA methylated (Sparago et al., 2004; Prawitt et al., 2005; Beygo et al., 
2013; Poole et al., 2012; Demars et al., 2010; Abi Habib et al., 2014). In addition, the 
penetrance of BWS clinical features ranges from no apparent phenotypes to severe 
growth defects (Beygo et al., 2013; Abi Habib et al., 2014). Thus, it is challenging to 
address if the genetic lesions are sufficient to cause abnormal IC1 hypermethylation, 
deregulation of H19/IGF2 imprinting, and/or development of BWS. The correlation 
between methylation changes and genetic lesions suggest heritability of pathological 
epigenotype, making the molecular investigation of these mutations particularly 
important.  
In this study, we showed that maternal transmission of hIC1 can functionally 
replace mIC1, by properly regulating imprinted expression and hIC1 methylation. Thus, 
our finding poses the exciting possibility of modeling IC1 mutations associated with BWS 
(Figure 1.7) in mouse via maternal transmission. This endeavor has been initiated in 
collaboration with the laboratory of Dr. Andrea Riccio. Mouse models with 1.8kb and 
2.2kb IC1 microdeletions (Figure 1.7) were generated in a similar manner to the H19hIC1 
allele, and both alleles are currently being analyzed. Preliminary data suggest that 
maternal transmission of both alleles leads to biallelic Igf2 expression, gain of 
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methylation at IC1, and overgrowth phenotype (personal communication with Dr. Andrea 
Riccio). It will be interesting to compare the phenotypes of mice inheriting the two 
microdeletion alleles. Of note, Beygo et al. reported that individuals with 2.2kb deletion 
exhibit less severe clinical phenotypes compared to those with 1.8kb deletion (Beygo et 
al., 2013).     
Disease modeling of SRS 
Despite IC1 hypomethylation being the most common epimutation found among 
SRS individuals (Figure 1.6) (Yamazawa et al., 2008), the molecular mechanism 
underlying the phenotype remains elusive. Obstacles in addressing this question include 
mosaicism of the epimutation in patients as well as lack of a suitable genetic model 
system. We suggest that the paternal transmission of hIC1 in a mouse can be used to 
study molecular mechanisms underlying SRS associated with IC1 hypomethylation. To 
this end, pursuing the rescue experiments with the H19△H19 and the H19miR-675mut alleles 
(Chapters 2.8.1 and 2.8.2) will elucidate the extent to which H19 lncRNA and miR-675 
contribute to the SRS-like phenotype. In addition, identifying tissue-specific (i.e. 
embryonic endodermal and mesodermal tissues and extraembryonic tissues) pathways 
altered by IC1 hypomethylation may shed light on whether the phenotypes underlying 
SRS are due to an altered physiology of one particular tissue or due to a combinatorial 
change in multiple tissues.  
Investigating the species-specific regulation of the H19/Igf2 locus 
Evidence of incomplete histone reprogramming at hIC1 suggests that the 
mechanism regulating histone reprogramming at IC1 in the germline has diverged 
between mouse and human. In this regard, it would be interesting to determine if an IC1 
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ortholog of a species more closely related to mouse could recapitulate the wild-type 
epigenetic pattern upon paternal transmission. This approach will provide insights into 
the extent to which mechanisms regulating the ICR reprogramming in the germline are 
conserved across mammalian evolution. Of note, recent studies have identified different 
features of germline epigenetic reprogramming between mouse and human. 
Interestingly, DNA methylation erasure at ICRs starts earlier in development in human 
(before PGCs colonize the genital ridges) compared to mouse (upon PGCs colonization 
of the genital ridges) (Gkountela et al., 2015; Guo et al., 2015; Hackett et al., 2013; Tang 
et al., 2015). The precise timing of DNA methylation establishment in the human germ 
cells remains to be determined. Nonetheless, differences in the length of gestation or the 
timing of developmental cues might account for the incomplete reprogramming of hIC1 
in mouse. 
 It is also possible that in the normal human context, the maternal hIC1 has a 
novel regulatory function (that is not present in mouse) of silencing the IGF2 expression 
and enhancing H19 expression. This human-specific function of the maternal hIC1 may 
be incompatible with the mouse system, acting dominantly on the mouse paternal allele. 
Such a neomorphic allele could recruit unknown transcription factors or form a specific 
three-dimensional chromatin conformation and/or an epigenetic landscape by recruiting 
chromatin modifying enzymes, leading to a preferential expression of H19, while 
silencing Igf2 expression. This hypothesis could be tested by generating an allele where 
hIC1 is inserted next to the endogenous mIC1. Imprinted expression of H19 and Igf2 and 
DNA methylation and histone modification at the locus can be measured. If hIC1 has a 
dominant effect in abrogating the normal function of the mIC1 on the paternal allele, this 
could suggest a neomorphic function of hIC1 (or potentially a novel regulatory role of 
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endogenous hIC1), although the possibility of hIC1 acting as a dominant CTCF-
dependent insulator compared to mIC1 cannot be excluded. If having an intact mIC1 at 
the endogenous locus preserves the normal imprinting function and male germline 
reprogramming of the hIC1 sequence, this will argue against the idea of hIC1 acquiring a 
neomorphic function. This result would rather suggest that the insertion of hIC1 can be 
influenced by the surrounding sequence or epigenetic landscape at the locus.        
Male germ cell analyses 
Given the well-described antagonistic relationship between the activating histone 
modification marks and DNA methylation (Chapter 1.1.2), we speculate that the 
abnormal enrichment of H3K4me2 at the hIC1 is inhibitory to the complete establishment 
of DNA methylation. However, it is equally possible that the hypomethylated state of 
DNA has attracted H3K4me2 at hIC1 by an unknown mechanism. More detailed time 
course analyses of DNA methylation and H3K4me2 enrichment in the PGCs and early 
stage male germ cells, such as spermatogonia, will provide insights into such an 
hypothesis.  
Alternatively, there might exist an inherent difference between mIC1 and hIC1 in 
acquisition of methylation. A non-coding transcript is detected at mIC1 during 
methylation acquisition in the male germ cells (Henckel et al., 2012), suggesting a 
potential role of transcription in methylation establishment at mIC1. Whether the same 
holds true at the endogenous hIC1 remains to be determined. Nevertheless, it would be 
worth investigating whether the expression of the non-coding transcript is disrupted in 
the male germ cells upon replacement of the mIC1 with hIC1. This result will support the 
growing agreement that transcription plays an important role in DNA methylation 
establishment at the ICRs, at least in mouse. 
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4.2 Patient-derived human cell based model  
Lineage-specific differentiation of the iPSCs 
The iPSCs derived exhibit stable and expected DNA methylation status at the 
pUPD11-relevant ICRs—IC1 and IC2. We also verified that pUPD11 EBs express higher 
levels of IGF2 compared to the non-pUPD11 EBs. To characterize pUPD11 in a 
disease-relevant context, we plan to differentiate select iPSC lines into hepatocytes. This 
work is ongoing in collaboration with the CHOP human ES/iPS cell core facility. The 
stability of methylation at IC1 and IC2 and the expression of H19 and Igf2 during 
different stages of differentiation will be carefully monitored. Ultimately, our goal is to 
perform RNA-sequencing in the cell lines to identify molecular pathways affected by 
pUPD11. Comparing gene expression profiles of different pUPD11 lines may shed light 
on the contribution of non-imprinted genes within the UPD region in the BWS disease 
etiology. Moreover, the non-pUPD11 iPSCs can be engineered to model other IC1 
mutations (Figure 1.7). Establishment of these genetically-matched cell lines will 
facilitate deconstructing the genotype-phenotype relationship in BWS.   
DLK1-DIO3 hypermethylation 
 The significance of hypermethylation of the DLK1-DIO3 locus in iPSCs is unclear. 
Different parental cell sources, culture conditions, and passaging techniques used in the 
reprogramming experiments make it difficult to identify the source for this 
hypermethylation (Nazor et al., 2012).  Several groups have investigated the 
mechanisms underlying the DLK1-DIO3 hypermethylation, and found the involvement of 
post-translational histone modifying enzymes, DNA methyltransferases, long non-coding 
RNAs, and maternal factors (Kaneko et al., 2014; McDonald et al., 2016; Stadtfeld et al., 
2010, 2012; Stelzer et al., 2014; Xu et al., 2015). Of note, individuals with pUPD14, in 
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which maternally expressed non-coding RNAs are repressed and paternally expressed 
protein-coding genes are upregulated, display postnatal growth and mental retardation 
and skeletal defects (Rocha et al., 2008). These suggest that the regulation at this locus 
is complex and its effect in human iPSC quality merits further investigation. 
The effect of VC in DLK1-DIO3 hypermethylation 
In the IMR91 fibroblasts reprogramming experiment with and without VC, failure 
to maintain the DLK1-DIO3 methylation might be attributed to the insufficient dosage or 
duration of VC treatment. It will be interesting to see whether further culturing the human 
iPSCs with VC could revert the DLK1-DIO3 hypermethylation. Of note, culturing the 
mouse iPSCs with VC for 15 passages did not revert the Dlk1-Dio3 hypermethylation 
(Stadtfeld et al., 2012), suggesting that VC is mainly effective in the early stage of 
mouse iPSC reprogramming at this locus. Nevertheless, dose-response and time-course 
experiments of the VC supplementation during human iPSC reprogramming/culture will 
elucidate the extent to which VC protects the human DLK1-DIO3 locus from becoming 
hypermethylated. 
4.3 Conclusions 
Study of genomic imprinting is meaningful in understanding mammalian 
development and human health. In addition, the unique but conserved regulation of 
genomic imprinting can provide insights into mammalian evolution at both molecular and 
physiological level. Proper regulation of genomic imprinting requires correct epigenetic 
reprogramming in the germline as well as stable maintenance of the imprinted state in 
the somatic cells. Therefore, comprehensive knowledge on mechanisms of genomic 
imprinting requires studies in various cell types including embryonic, extraembryonic, 
and germ cell lineages, at various developmental stages. Similarly, it is likely that 
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mechanisms underlying alterations associated with human imprinting disorders are 
highly context-and stage-dependent. Because it is not always feasible to perform 
experiments in the desired cell types of the right developmental stage, especially with 
human samples, developing and taking advantage of various model systems is crucial in 
the study of genomic imprinting. The use of the humanized mouse model and the 
patient-specific iPSCs to interrogate mechanisms of imprinting, described in this 
dissertation, represents an example of such an endeavor. Continuous efforts in 
developing diverse models, by recognizing the limitations while maximizing the benefits 
of each model system, are instrumental to the field of imprinting.   
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5.1 Generation of H19hIC1 mouse 
Targeting vector  
To generate the phIC1-neo target vector, first the backbone KpnI site was 
removed from the Δ3.8kb-5’ target vector (Thorvaldsen et al., 2002), leaving a unique 
KpnI site between the 5’ homology arm and the NeoR cassette. Into this KpnI site, we 
cloned the 4.8kb hIC1 sequence (from NsiI to EcoRI) isolated from human genome 
library that was engineered to contain KpnI sites (at the NsiI and XhoI sites) without 
destroying the endogenous sites (Stratagene) (Stadnick et al., 1999). The phIC1-neo 
target vector was designed to replace both the endogenous mouse IC1 and 1.3 kb G-
rich repeat sequence with the hIC1 sequence, to make the distance between the 
targeted hIC1 and the H19 promoter equivalent to what is observed at the orthologous 
human locus. We have previously shown that the G-rich repeat sequence is dispensable 
for normal H19/Igf2 imprinting in mouse (Thorvaldsen et al., 2002). 
ESC targeting, mouse breeding, and genotyping  
phCI1-neo target vector was linearized and electroporated into E14 ESCs (Kühn 
et al., 1991) as described previously (Thorvaldsen et al., 2002). G418-resistant positive 
clones were isolated and correct targeting was validated by Southern blot analyses 
using the same external probes as described previously (Thorvaldsen et al., 2002) with 
following changes. gDNA was digested with EcoRV-MluI and hybridized to the 5’probe A. 
The internal probe C was isolated by PCR amplification of a WT B6 mouse gDNA using 
primers 5’-ATTCCTCTCCAACCCTAGCTCAG-3’ and 5’-
GGATCTGCCAAGGTGCTATTGC-3’ and hybridized to gDNA digested with StuI (Figure 
2.2A and B). Correctly targeted clones were injected into B6 blastocysts by the 
Transgenic and Chimeric Mouse Facility at the University of Pennsylvania. Obtained 
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chimeras were mated to B6 mice. Germline transmission of the targeted allele was 
confirmed within the agouti progeny by isolating gDNA from ear punch samples and 
performing Southern blot analysis as described above and PCR-based genotyping with 
primers PGNeo0.2 and HSEQR1 (Tables 5.1 and 5.2). All studies adhered to 
procedures approved by the Institutional Animal Care and Use Committee at the 
University of Pennsylvania. 
Germline transmission of the H19hIC1-neo was verified by PCR-based genotyping 
as described above. To excise the neoR cassette (flanked by loxP sites), heterozygote 
female mice with H19hIC1-neo allele were crossed to B6 male mice that express Cre 
recombinase under the control of the adenovirus EIIa promoter (EIIA-Cre) (Jackson 
laboratories). NeoR excision was verified using Southern blot analysis and PCR-based 
genotyping with primers HIC1SEQF1 and TV23armSEQR1 (Figures 2.2A and B and 
Tables 5.1 and 5.2). Mice lacking the NeoR cassette (H19hIC1) were maintained by 
crossing the H19hIC1/+ female mice to wild-type B6 male mice and selecting for progeny 
carrying the H19hIC1 allele as determined by PCR analysis. For all comparisons, 
heterozygous knock-in offspring and embryos were compared with their wild-type 
littermates. Both males and females were included. For all genotypes, the maternal 
allele is listed first and the paternal allele second. 
5.2 Generation of H19△H19 mouse 
gRNA design 
gRNA sequences were designed using the program (http://www.genome-
engineering.org/crispr/?page) and are shown below. PAM sequences are underlined. 3A 
and 3B target 3’end, and 5A and 5B target 5’end of the H19 gene. 
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 Pair A  Pair B 
3A CTTCAATATAATGCGACTCA TGG 3B CAATATAATGCGACTCATGG GGG 
5A AACGTGCGCTGGAACGATAC AGG 5B ATCAGTACATGGCCCCGCCG GGG 
 
gRNA generation and injection 
All procedures were done per guidance of Dr. Catherine May in the laboratory of 
Dr. Klaus Kaestner. The protocol provided by Dr. Catherine May was modified from 
Yang et al. (Yang et al., 2014). For sgRNA preparation, px335 plasmid (Addgene 
#42335) was PCR amplified using the primer sets:  
Forward: 5’-TTAATACGACTCACTATAGGNNNNNNNNNNNNNNNNNNNNgttttagagctagaaatagc-
3’ 
Reverse: 5’-AGCACCGACTCGGTGCCACT-3’ 
 
The underlined 20 nucleotides of the forward primer were substituted with each 
gRNA sequence excluding the PAM sequence. Reverse primer is universal for all PCR 
reactions. PCR reaction was setup using the Phusion high-fidelity DNA polymerase 
(NEB, cat. No. M0530). To get enough materials for in vitro transcription, 2-3 PCR 
reactions were setup per gRNA. 
Component Amount (μl/reaction) 
5X Phusion HF Buffer 20 
10mM dNTPs 2 
10uM Primer Mix  5 
DNA Polymerase 1 
Template DNA (pX335), 10 ng 2 
H2O 70 
Total Volume 100 
 
Cycle number Denature Anneal & Extend Final Extend 
1 98 °C, 30s     
2-34 98 °C, 30s 72 °C, 20s   
35     72 °C, 1 min 
Hold at 4 °C       
 
PCR products were ran on a 2% agarose gel. Once ~117bp products are verified, 
PCR products are gel-purified using the Qiagen Gel Extraction kit according to the 
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manufacturer’s instruction. One column was used to pool the same PCR product and 
DNA was eluted in 15μl RNAse free water. In vitro transcription of gRNA was setup 
using the gel-purified product as templates. T7 High Yield RNA Synthesis kit (NEB, 
E2040S) was used according to the kit protocol. More than 2 tubes of reactions per 
gRNA were setup to increase the yield. 
Component Amount (μl/reaction) 
10X Reaction Buffer 1.5 
ATP 1.5 
GTP 1.5 
UTP 1.5 
CTP 1.5 
Template DNA (500 ng) X 
T7 RNA polymerase Mix 1.5 
Nuclease-free H2O X 
Total 20 
 
Reactions were incubated at 37°C overnight. Transcribed gRNA was purified 
using the MEGAclear kit (Life Technologies) according to the kit protocol. To prevent the 
injection needles from being clogged during microinjection, the eluted gRNA was spun 
twice at top speed at 4°C for 20min, with each spin followed by transfer of suspension to 
a new tube. The eluted gRNA was concentrated according to the protocol so that the 
final concentration is around 1-2μg/μl. RNA quality and quantity were checked using a 
bioanalyzer. Injection mix was prepared as follow: 
Component 
Stock 
Concentration Stock Vol. (ul) Final Concentration 
sgRNA (Left) 500 ng/μl 3 50 ng/μl 
sgRNA (Right) 500 ng/μl 3 50 ng/μl 
Cas9 mRNA 1 μg/μl 3 100 ng/μl 
Injection buffer*   21   
Total   30   
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*Injection buffer: 10 mM Tris / 0.1 mM EDTA, pH 7.5 prepared with sterile water.  
The injection mix was spun at top speed at 4°C for 20min, and the suspension 
was transferred to a new tube for injection. Either pair A or pair B was injected per 
zygote stage embryo by the Transgenic and Chimeric Mouse Facility at the University of 
Pennsylvania. 
Mouse breeding and genotyping 
Obtained chimeras and germ line transmission animals were PCR-genotyped for 
the H19△H19 allele using primers (Figure 2.14 and Tables 5.1 and 5.2). The H19△H19 
allele is maintained/backcrossed in B6 background via paternal transmission.  
5.3 Gene Expression Analysis  
Sample collection and processing 
All mouse tissue samples were flash-frozen in liquid nitrogen and stored at -80°C. 
Tissues were processed using the polytron homogenizer for the neonatal liver and 
tongue samples, or syringes and needles for the embryonic liver and placenta samples.  
iPSCs were manually dislodged from plates using pipette tips or cell scrapers 
and EBs were dissociated using 0.25% Trypsin-EDTA. iPSCs were pelleted and stored 
at -80°C. The dissociated EB samples were pelleted, put in 1ml of TRIzol, incubated at 
room temperature for 10min, then stored at -80°C. 
RNA isolation and cDNA synthesis 
RNA from mouse tissues, iPSCs, and EBs was isolated using TRIzol according 
to the manufacturer’s instructions. RNA was precipitated using glycogen and 100% 
106 
 
isopropanol. Isolated RNA was treated with DNase (Promega) to remove genomic DNA 
contamination and cDNA was synthesized using Superscript III reverse transcriptase 
(Invitrogen) and random primers (Roche).  
Allele-specific expression 
10ng of cDNA was used for allele-specific expression assay. Allele-specific 
expression of H19 and Igf2 was determined by RT-PCR followed by restriction digestion 
using RFLP between the B6 and CAST alleles. H19 RT-PCR fragment was digested 
with Cac8I, and Igf2 RT-PCR fragment was digested with MluCI for 3 hours at 37°C. 
Primers and PCR conditions are listed in Tables 5.2 and 5.3. 
Total expression 
5ng of cDNA was used for qRT-PCR assay. Power SYBR Green mater mix 
(Applied Biosystems) and primers in final concentration of 0.2μM were used on an ABI 
7300 machine. Each sample was run in triplicate, and the mean value of triplicate is 
plotted in graphs. For each primer set, reaction efficiency (E) was calculated using 
standard curve, and E^-Ct value of each gene was normalized to E^-Ct values of 
housekeeping genes.  
For analyses in mouse samples, total expression levels of H19, Igf2, Igf1r, and 
IGN genes were measured relative to the geometric mean of expression levels of Arbp, 
Nono, and Rpl13a. For the y-axis on the graph, the mean value of +/+ is arbitrarily set as 
1. For analyses in human samples, total expression levels of pluripotency markers, EB 
markers, H19, and IGF2 were measured relative to the geometric mean of expression 
levels of GAPDH and PPIG. 
Total expression levels of miR-675-3p and miR-675-5p were determined relative 
to the level of snoRNA202 by using a separate RT kit (TaqMan MicroRNA Reverse 
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Transcription Kit, Thermo Fisher Scientific), qRT-PCR primers (Assay Id 001232, 
001941, 001940, Thermo Fisher Scientific), and a PCR master mix (TaqMan Universal 
PCR Master Mix, catalog number 4304437, Thermo Fisher Scientific) according to 
manufacturer’s protocol. Primers and PCR conditions for all expression analyses are 
listed in Tables 5.1, 5.2, and 5.7.  
5.4 DNA Methylation Analysis  
Sperm sample collection and preparation 
H19hIC1/+ mouse mature sperm was collected from cauda epididymis and vas 
deferens from minimum 8 weeks old, primed male mice. For the human sperm samples, 
discarded semen samples were obtained from the University of Pennsylvania Fertility 
Clinic following routine semen analysis. As all samples were discarded and de-identified, 
the University of Pennsylvania Institutional Review Board determined this study was 
exempt from requiring informed consent. Semen samples were washed with PBS to 
remove seminal fluid. The resulting human sperm were somatic cell lysed (0.1% SDS, 
0.5% Triton-X-100) for 30min on ice, counted, and stored at -80°C until further use. 
gDNA isolation 
Collected mouse neonatal and embryonic tissues, human fibroblasts, iPSCs, and 
EBs were first digested with 12μl of 20mg/ml proteinase K (Sigma-Aldrich) in 500μl lysis 
buffer (50mM Tris, pH8.0, 100mM EDTA, 0.5% SDS) overnight at 55°C. For both mouse 
and human sperm, 500μl sperm-specific lysis buffer (20mM Tris-HCl pH8.0, 20mM 
EDTA, 4% SDS, 200mM NaCl) was used and 5μl of 2-mercaptoethanol (Sigma-Aldrich) 
was added, in addition to the 12μl of 20mg/ml proteinase K.  
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For all samples, gDNA was isolated using Phenol:Chloroform:Isoamyl Alcohol 
(Sigma-Aldrich P3803) and ethanol precipitation with 7.5M ammonium acetate. All 
isolated gDNA samples were resuspended in water and stored at-20°C or resuspended 
in 1xTE and stored at 4°C.  
Bisulfite treatment 
For mouse neonatal and embryonic tissues, mouse and human sperm samples, 
and iPSCs, 250-1000ng of gDNA was subjected to bisulfite mutagenesis using the 
Epitect kit (Qiagen) according to the manufacturer’s protocol. Pools of 120-200 oocytes 
were collected from 25-28 days old heterozygote (H19hIC1/+) female mice and pools of 
40-50 two-cell embryos were collected by crossing H19hIC1/+ male mice to superovulated 
WT B6 female mice. Blastocyst was individually collected (single blastocyst was used as 
a single data point). Oocytes, two-cell embryos, and blastocysts were subjected to 
bisulfite mutagenesis using the Epitect plus kit (Qiagen) according to manufacturer’s 
protocol.  
20-25ng bisulfite-mutagenized DNA (for mouse neonatal and embryonic tissues, 
mouse and human sperm samples, and iPSCs), 24-100 oocytes, ~18 two-cell embryos, 
or half blastocyst equivalent of bisulfite-mutagenized DNA was used per PCR for 
pyrosequencing, cloning and sequencing, and COBRA.  
Pyrosequencing was performed as previously described (de Waal et al., 2014). 
PCR for cloning and sequencing for the mIC1 was performed using nested PCR and 
PCR beads as previously described (de Waal et al., 2014). PCR for cloning and 
sequencing for the hIC1 was performed using PyroMark PCR Kit (Qiagen). For all 
cloning and sequencing experiments, StrataClone, PCR cloning Kit (Agilent 
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Technologies) was used. For COBRA, the amplified PCR products were digested with 
appropriate restriction enzymes (HPYCH4IV for IC1, RsaI for IC2) for 3 hours at 37°C; 
enzymes were then inactivated for 10 min at 65°C; bands were resolved using 12% 
polyacrylamide gel and were quantified using ImageJ. For all PCR-based methylation 
analyses, minimum of two rounds of PCR was performed per analysis, when enough 
DNA was available. Primers, PCR conditions, and relevant restriction enzymes used for 
all methylation analyses are listed in Tables 5.1, 5.3, 5.5, and 5.6.  
5.5 Histology  
Histology was performed as previously described (de Waal et al., 2015).  
5.6 Mouse Spermatogenic Cell Fractionation  
Round spermatid fraction of mouse spermatogenic cells were collected using 
STA-PUT in two independent replicates and purity of each fraction was verified as 
described in (Bryant et al., 2013, 2015) and per guidance of Dr. Lacey Luense. Each 
collection used both testes of 12 heterozygous (H19hIC1/+) primed male mice. Purity of 
each pool was measured as 87% (pool 1) and 86% (pool 2).  
5.7 Isolation of mouse embryonic fibroblasts (MEFs)  
MEFs were isolated from individual day 12.5 embryos in a B6 background as 
previously described (Verona et al., 2008). 
5.8 Chromatin Immunoprecipitation (ChIP)-qRT-PCR Analysis  
ChIP was carried out as previously described in (Bryant et al., 2015) and as per 
guidance of the protocol from the laboratory of Dr. Shelly Berger. Round spermatids and 
MEFs were cross-linked using 1% formaldehyde in Phosphate-buffered saline (PBS) for 
10 min at room temperature. The reaction was quenched using glycine at final 
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concentration of 125mM for 5 min at room temperature. Cells were spun down at 
1500rpm for 5min, washed with cold PBS(1X), and flash frozen in liquid nitrogen and 
stored at -80°C until processed for ChIP. After cell lysis, lysates were sonicated using 
Covaris S220 sonicator for 20 min with 5% duty cycle, 140 W of peak incident power, 
200 cycles per burst, and 6°C bath temperature. 1/10 volume of 10% triton X-100 in PBS 
was added to the sonicated lysate, and the lysate was spun at 14000rpm for 10 min at 
4°C. Supernatant was saved. Protein content of the lysate was measured by the 
bicinchoninic acid assay. For each IP, ~200μg of protein and 30μl of Dynabeads Protein 
G (Thermo Fisher Scientific), with 2.5 to 5μg of IgG (Santa Cruz Biotechnology sc-2027), 
H3 (Abcam ab1791), and H3K9me3 (Abcam ab8898), 5μl of H3K4me2 (EMD Millipore 
07-030), or 10μl of CTCF (EMD Millipore 07-729) were used. Following elution of ChIP 
DNA, qRT-PCR was performed as described in Chapter 5.3 using the Power SYBR 
Green master mix and the ABI 7300 machine. For qRT-PCR, two different sets of primer 
pairs were used for assays b and j (Figure 2.2C) and a mean value of the two primer 
sets was plotted on the graph. All other assays used one set of primer pair. Each ChIP 
signal was calculated as percent input of each IP normalized to non-specific IgG 
(percent input IP - percent input IgG). ChIP-qRT-PCR primers are listed in Table 5.3. 
5.9 Patient clinical features and genetic testing 
Clinical information, clinical testing results, and fibroblast samples were collected 
from the Children’s Hospital of Philadelphia BWS registry/repository (IRB #13-010658). 
All four patients presented with hyperinsulinism, macrosomia, macroglossia, 
omphalocele, and hemihyperplasia. Genome-wide single nucleotide polymorphism 
(SNP) microarray analysis was carried out using the Illumina CRC BeadChip as 
previously described (Conlin et al., 2010). 
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5.10 iPSC generation and culture 
* All reagents are from Life Technologies, unless otherwise specified first time 
mentioned. 
Fibroblast derivation and culture 
Skin samples were collected during surgical procedures and fibroblasts were 
dissociated using collagenase Type 2 (Worthington) in RPMI 1640 (1.6 g in 200 ml) for 
30 minutes. In preparation for reprogramming, Patient 1, 2, 3 and 4 fibroblasts and 
normal human fetal male fibroblasts IMR-91 (Coriell Institute for Medical Research) were 
cultured in fibroblast media (RPMI with 20% fetal bovine serum (Hyclone SH30070.03), 
1X penicillin/streptomycin, 1X GlutaMAX)) and fed every 2 days.                                                                                     
Viral Reprogramming 
Patient 1 fibroblasts were reprogrammed with the infection of the inducible stem 
cell cassette (STEMCCA) and reverse tetracycline-controlled transactivator (rtTA) virus 
(Sommer et al., 2009) as previously described (Anguera et al., 2012; Woo et al., 2016). 
5x104 Patient 1 fibroblasts were seeded onto one well of a 6-well plate. The following 
day, in fibroblast media, cells were infected with STEMCCA (100μl) and rtTA (80μl) 
viruses prepared by (Woo et al., 2016). Two days after infection, the media was replaced 
with fresh fibroblast media. The following day, cells were passaged onto three 10 cm 
gelatinized (0.1% gelatin) plates in fibroblast media with 2μg/ml doxycycline (Sigma 
9891) and transferred to low oxygen (5%CO2, 4%O2) incubator (a portion of infected 
cells were also plated onto 12-well plates -/+ 2μg/ml doxycycline (Sigma 9891) to test for 
efficiency of infection by measuring OCT4 induction by immunohistochemistry, by 
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method described below.) For subsequent days of reprogramming, cells were fed daily 
with WIBR hES media (DMEM/F12 with 15% fetal bovine serum, 5% KnockoutTM Serum 
Replacement, 0.1875% Sodium Bicarbonate, 1X nonessential amino acids, 1X 
penicillin/streptomycin, 1X GlutaMAX, 0.1mM 2-mercaptoethanol, 10ng/ml βFGF (R&D 
Systems)) and freshly added 2μg/ml doxycycline, as described (Woo et al., 2016).                                                               
Episomal reprogramming 
Patient 2, 3, and 4 fibroblasts and IMR91 fibroblasts (Coriell Institute for Medical 
Research Cell Repository) were reprogrammed with episomal plasmids as previously 
described (Bershteyn et al., 2014; Okita et al., 2011). To reprogram, we electroporated 
600,000 cells with plasmids (1μg of each) CXLE-hOCT3/4-shp53, pCXLE-sSK, pCXLE-
HUL, and pCXLE-EGFP plasmid (Okita et al., 2011) (Addgene) using the Neon® 
Transfection System 100-ml-kit according to manufacturer’s instruction. Conditions for 
electroporation were 1,650 V, 10ms, and three pulses (Bershteyn et al., 2014). As 
described by (Okita et al., 2011), pCXLE-EGFP was used to monitor the efficiency of 
electroporation and gradual loss of plasmid/eGFP expression with prolonged culture. 
Cells were recovered in fibroblast media and plated onto 10 cm and 6 cm gelatinized 
plates and incubated in a standard high oxygen incubator. The following day, media was 
changed to the WIBR hES media, and plates were moved to a low oxygen incubator and 
fed daily for 6 days. During initial 7 days of reprogramming of the patient fibroblast 3 and 
4 and IMR91 fibroblasts, the WIBR hES media was supplemented with 37.5μg/ml 
Vitamin C (VC) (Sigma 49752), based on analysis of (Chung et al., 2010) and 
considering the amount of VC already in the KnockoutTM Serum Replacement (Stadtfeld 
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et al., 2012). On the 7th day after electroporation, fibroblasts were expanded onto 
multiple 6 cm and 10 cm gelatinized plates and fed daily with WIBR hES media, 
analogous to our viral reprogramming method (Woo et al., 2016).  
Picking and culturing iPSCs  
Colonies were picked between day 18 and 28 of reprogramming into media with 
50% WIBR hES media and 50% serum free iPSC media (DMEMF12 with 20% 
KnockoutTM Serum Replacement, 1X nonessential amino acids, 1X 
penicillin/streptomycin, 1X GlutaMAX, 0.1mM b-mercaptoethanol, 10ng/ml βFGF (R&D 
Systems)). Colonies were picked and passaged onto gelatin coated 6-well plates that 
were plated with 125,000 Mitomycin C treated CF1 mouse embryonic 
fibroblasts(MEFs)/well. Clones were weeded and fed every 1-2 days with serum free 
iPSC media. iPSCs were manually passaged every 5-7 days. On the days of picking, 
passaging wells with <5 colonies, and thawing iPSCs, 0.5mM ROCK inhibitor 
(StemMACSTMThiazovivin) was routinely added to media; ROCK inhibitor was removed 
the following day by changing to fresh media. 
5.11 EB generation 
* All reagents are from Life Technologies, unless otherwise specified first time 
mentioned. 
iPSCs were differentiated to EBs as previously described (Anguera et al., 2012). 
iPSCs were dislodged from MEF feeder cells using pipette tips or cell scrapers and 
transferred to low attachment plates (Corning) in 50% WIBR hES media and 50% EB 
differentiation media (DMEMF12 with 20% fetal bovine serum, 1X nonessential amino 
acids, 1X penicillin/streptomycin, 1X GlutaMAX, 0.1mM 2-mercaptoethanol). ROCK 
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inhibitor was added for the first day of EB differentiation at final concentration of 0.5mM 
and removed the next day by changing to fresh EB differentiation media. After 7 days, 
EBs were transferred to gelatin-coated plates and cultured for 7 days. Media was 
changed every other day. EBs were collected on day 14. 
5.12 PCR Genotyping of fibroblasts and iPSC clones 
Microsatellite marker AFM217YB10 was used to genotype parental alleles of 
patient 1 and 2 gDNA. Single Nucleotide Polymorphisms (SNP) rs3741216 (T/A) in 
patient 3 and rs10840159 (A/G) in patient 4 were used for genotyping iPSC clones, 
facilitated by restriction enzyme digest of polymorphisms. See Table 5.4 for details.  
5.13 Characterization of iPSCs 
Immunofluorescence staining  
Cells were fixed in 4% paraformaldehyde (Electron Microscopy Sciences) for 
20min at room temperature, permeabilized in 0.1% Triton-X100 (EMD), blocked with 3% 
bovine serum albumin (Calbiochem), and incubated overnight at 4°C in following primary 
antibodies: SSEA1 (1:100, Millipore), SSEA3 (1:100, Millipore), SSEA4 (1:100, Millipore), 
TRA1-60 (1:100, Millipore), TRA1-81 (1:100, Millipore) and Oct4 (1:250, Novus 
biologicals). Cells were then incubated with appropriate secondary antibodies: Alexa 
Fluor 488 goat anti-mouse IgG (1:1000, Life Technologies), Alexa Fluor goat anti-mouse 
IgM (1:1000, Life Technologies) and FITC-goat α-rabbit IgG (1:1000, Novus biologicals) 
for 30min at room temperature. 
Karyotyping  
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Cells were treated with 0.2ug/ml Colcemid (Sigma) for 4 hours at 37°C, collected 
using 0.25% Trypsin and lysed in 0.56% (w/v) KCl for 25min at room temperature. Cells 
were fixed in methanol:acetic acid (3:1) solution, spread to slides, stained with Giemsa 
(Sigma). 
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Table 5.1 PCR conditions for the H19hIC1 allele 
 
Gene/ 
region 
assayed 
Tissue Genotype PCR conditions Annealing 
Temp (°C) 
(TA) 
Cycle 
number 
(#) 
Genotyping 
- All All 2min denaturation at 94°C; # cycles 
of 15sec at 94°C, 15sec at TA, and 
20sec at 72°C; 2min extension at 
72°C 
58-60 35 
Allele-specific expression 
H19 P0 liver;  
P0 tongue; 
E15.5 liver; 
E15.5 
placenta; 
E9.5 embryo 
 
 
 
 
WT, KI* 
 
 
 
 
 
 
2min denaturation at 95°C; # cycles 
of 15sec at 95°C, 10sec at TA, and 
20sec at 72°C; 5min extension at 
72°C 
 
 
 
 
60 
 
 
 
 
 
26-30 
Igf2 P0 liver; 
P0 tongue 
WT, KI  
 
 
 
58 
 
27-29 
E15.5 liver; 
E15.5 
placenta; 
E9.5 embryo 
WT 26-28 
E15.5 
placenta; 
E15.5 placenta 
E9.5 embryo 
KI 31-33 
Pyrosequencing 
hIC1 
(CTS6) 
All All 15min denaturation at 95°C; # 
cycles of 30sec at 95°C, 30sec at 
TA, and 30sec at 72°C; 5min 
extension at 72°C 
55 45 
All mouse 
ICRs 
except for 
Snrpn ICR 
15min denaturation at 95°C; # 
cycles of 15sec at 95°C, 30sec at 
TA, and 15sec at 72°C; 10min 
extension at 72°C 
55 45 
 
Mouse 
Snrpn ICR 
58 
Bisulfite sequencing 
mIC1 All All 1st round: 2min denaturation at 
94°C; # cycles of 30sec at 94°C, 
30sec at TA, and 30sec at 72°C; 
5min extension at 72°C 
50 40 
2nd round: 2min denaturation at 
94°C; # cycles of 30sec at 94°C, 
30sec at TA, and 30sec at 72°C; 
5min extension at 72°C 
58 35 
hIC1 
CTS1/2 
All All 15min denaturation at 95°C; # 
cycles of 30sec at 95°C, 30sec at 
TA, and 30sec at 72°C; 5min 
extension at 72°C 
58 45 
hIC1 CTS3 60 41 
hIC1 CTS4 58 41 
hIC1 CTS6 55 45 
 
*KI: hIC1 knock-in 
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Table 5.2 Genotyping and expression analyses primers for mouse studies 
 
Gene/region 
Assayed 
Primer name Sequence Reference 
Genotyping 
PGNeo0.2 CCACTTGTGTAGCGCCAAGTGCC 
Thorvaldsen et al., 2002 HSEQR1 CCACAGAGTCAGCATCCAC 
HIC1SEQF1 CCTTCACGGCTTTGACACTC 
This study 
 
TV23armSEQR1 GTCAACCGGAGGCACAGTAT 
H19-214 TTGTGGTGAGGCTGTCTTTG 
H19+2722 CCTATTCCCCATTCCATCCT 
Allele-specific expression 
H19 
 
HE2 TGATGGAGAGGACAGAAGGG 
De Waal et al., 2014 
 
HE4 TTGATTCAGAACGAGACGGAC 
Igf2 
 
Igf2-18 ATCTGTGACCTCTTGAGCAGG 
Igf2-20 GGGTTGTTTAGAGCCAATCAA 
Total expression 
Arbp 
  
ArbpqPCRF TCCCACTTACTGAAAAGGTCAAG 
This study 
 ArbpqPCRR TCCGACTCTTCCTTTGCTTC 
Nono 
  
NonoqPCRF GCTCGTGAGAAGCTGGAGAT 
Plasschaert and 
Bartolomei, 2014 
 
 
NonoqPCRR TTCTTGACGTCTCATCAAATCC 
Rpl13a 
  
Rpl13aqPCRF ATCCCTCCACCCTATGACAA 
Rpl13aqPCRR GCCCCAGGTAAGCAAACTT 
H19 
  
H19qPCRF GTCTCGAAGAGCTCGGACTG 
This study 
 H19qPCRR ACTGGCAGGCACATCCAC 
Igf2 
  
Igf2qPCRF CGCTTCAGTTTGTCTGTTCG 
Weaver et al., 2010 
 Igf2qPCRR GCAGCACTCTTCCACGATG 
Cdkn1c 
 
Cdkn1cqPCRF TCTCGGGGATTCCAGGAC This study 
Cdkn1cqPCRR ACGTTTGGAGAGGGACACC  
Gtl2 
 
Gtl2qPCRF TTGCTGTTGTGCTCAGGTTC This study 
Gtl2qPCRR ATCCTGGGGTCCTCAGTCTT  
Igf2r 
 
Igf2rqPCRF GCACAGAATCCAGACTAGCATTACA Varrault et al., 2006 
Igf2rqPCRR CCTCCTTATCAGCTTTAAATATGTCTTTCTT  
Dlk1 
 
Dlk1qPCRF CGGGAAATTCTGCGAAATAG This study 
Dlk1qPCRR TGTGCAGGAGCATTCGTACT  
Gnas 
 
Gnasexon1aqPCRF AGCGCGAGGCCAACAAAA Varrault et al., 2006 
Gnasexon1aqPCRR GTGCGTGGCCCGGTAGA  
Peg3 
 
Peg3qPCRF GGTGTGTGCGTAGAGTGCTG This study 
Peg3qPCRR TCCTCTTGCCAGTTGTCTCC  
Slc38a4 
 
Slc38a4qPCRF TCACACTGCTGTTTCCAAGG Bloise et al., 2012 
Slc38a4qPCRR CAGCCGGAAGAATGAAAATC  
Igf1r 
 
Igf1rqPCRF GTGGGGGCTCGTGTTTCTC Keniry et al., 2012 
Igf1rqPCRR GATCACCGTGCAGTTTTCCA  
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Table 5.3 Methylation anlyses and ChIP-qRT-PCR primers for the H19hIC1 allele 
 
Region 
assayed Primer name Sequence Reference 
Pyrosequencing 
hIC1 
 
 
 
 
hH19pyroseq2F 
Qiagen 
Assay name ADS003 
Catalog No PMC0007406 
 
 
hH19pyroseq2R-
biotinylated 
hH19pyroseq2 
seq 
For mouseIC1, Kcnq1ot1 ICR, Peg1 ICR, Peg3 ICR, Snrpn ICR, and IG-DMR, primers are described in (de Waal et 
al., 2014).  
Bisulfite sequencing 
mIC1 
 
 
 
BMsp2t1 GAGTATTTAGGAGGTATAAGAATT 
de Waal et al., 
2014 
 
BHha1t3 ATCAAAAACTAACATAAACCCCT 
BMsp2t2 GTAAGGAGATTATGTTTATTTTTGG 
BHha1t4 CCTCATTAATCCCATAACTAT 
hIC1 CTS1/2 
 
CTS1F GTATTTTTGGAGGTTTTTTATTTAG 
Beygo et al., 
2013 
 
 
 
 
CTS2R TCCCATAAATATTCTATCCCTCACTA 
hIC1 CTS3 
 
CTS3F GGGAGATGAGATATTTTGGTGATAATG 
CTS3R CCCCATCCAAAAAAAACTTAAAC 
hIC1 CTS4 
 
CTS4F TATAGGGTTTTTGGTAGGTTTA 
CTS4R CCATAAATATCCTATCCCTAATA 
hIC1 CTS6 
 
CTS6F GTAGGGTTTTTGGTAGGTATAGAGT Takai et al., 
2001 CTS6R CACTAAAAAAACAATTATCAATTC 
hIC1 CTS6 
(used for 
oocytes) 
 
hH19pyroseq2F 
Qiagen Assay name ADS003 
Catalog No PMC0007406 
Non-biotinylated reverse primer was used 
  
hH19pyroseq2R 
non-biotin 
 
ChIP-qRT-PCR 
mIC1 
 
 
 
 
 
 
mIC1chIPF2-assay b AATGCCTGATCCCTTTGTTG This study 
 mIC1chIPR2-assay b TACATATTGCTCGGCAGACG 
mIC1chIPF3-assay b AGCTTTGAGTACCCCAGGTTCA Delaval et al., 
2007 mIC1chIPR3-assay b GCCTCTGCTTTTATGGCTATGG 
mIC1chIPF4-assay c CTCTTTAGGTTTGGCGCAAT This study 
 mIC1chIPR4-assay c GCCCTATTCTTGGACGTCTG 
hIC1 
 
 
 
 
 
 
 
 
hIC1chIPF1-assay j CTGATTCCAGCAGCACAGAG 
This study 
 
 
 
 
hIC1chIPR1-assay j GTGTGAGCCTGACAGTGCAT 
hIC1chIPF2-assay j GGTCCCAGTCATGATCACCT 
hIC1chIPR2-assay j CTGAAGCTGGGACAGGAGAG 
hIC1chIPF4-assay i CCCGAGGGTTGTCAGAGATA 
hIC1chIPR4-assay i CTCCCCAACCTTCAACAATG 
hIC1chIPF5-assay k ACAGAATCGGTTGTGGCTGT 
hIC1chIPR5-assay k AGCCTTGGGTCACCTTCAG 
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Table 5.4 Genotyping assays for iPSCs 
 
Patient  
cell linesa 
Forward Reverse Restriction 
Enzyme 
Polymorphism 
Assayed 
Patient 1 GGGGCATCTGTGGCTA TCCGGTTTGGTTCAGG Not 
applicable 
AFM217YB10 
Patient 2 GGGGCATCTGTGGCTA TCCGGTTTGGTTCAGG Not 
applicable 
AFM217YB10 
Patient 3 AACACCTTAGGCTGGTGG TCGGAGCTTCCAGACTAG MseIb rs3741216 
This study 
Patient 4 AACACCTTAGGCTGGTGG TCGGAGCTTCCAGACTAG MscIb rs10840159 
 
a PCR conditions to assay Patients 1 and 2 microsatellite repeat marker: 94°C 2min, (94°C 30s, 57°C 30s, 
72°C 30s)x35 cycles, 72°C 5min. To assay Patients 3 and 4 SNPs, PCR conditions are: 94°C 4min, (94°C 
90s, 60°C 60s, 72°C 90s)x31 cycles. 
bThe common (maternal) allele of patient 3 gDNA is digested with MseI at rs3741216 (T/A); the common 
(maternal) allele of patient 9 gDNA is digested with MscI at rs10840159 (A/G).   
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Table 5.5 PCR conditions for methylation analyses of iPSCs 
  
Gene/ 
region assayed 
Restriction 
enzyme 
PCR conditions Annealing 
Temp (°C) 
(TA) 
Cycle 
number 
(#) 
Pyrosequencing 
hIC1 (CTS6) and  
SNRPN ICR 
Not 
applicable 
15min denaturation at 95°C; # cycles of 30sec 
at 95°C, 30sec at TA, and 30sec at 72°C; 5min 
extension at 72°C 
55 45 
IG-DMR and  
MEG3-DMR  
58 45 
 
Bisulfite sequencing 
hIC1 CTS3 Not 
applicable 
15min denaturation at 95°C; # cycles of 30sec 
at 95°C, 30sec at TA, and 30sec at 72°C; 5min 
extension at 72°C 
60 41 
COBRA 
IC1 (CTS3) 
 
HPYCH4IV 15min denaturation at 95°C; # cycles of 30sec 
at 95°C, 30sec at TA, and 30sec at 72°C; 5min 
extension at 72°C 
60 41 
IC2 RsaI 
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Table 5.6 Methylation analyses primers for iPSCs  
 
Region 
assayed Primer name Sequence Reference 
Pyrosequencing 
hIC1 
 
 
 
 
hH19pyroseq2F Qiagen 
Assay name ADS003 
Catalog No PMC0007406 
 
 
hH19pyroseq2R-
biotinylated 
hH19pyroseq2 
seq 
IG-DMR 
Assay1 
 
CG4Assay1F 5'Biotin- ATTATTGAATTGGGTTTGTTAGTAGT 
Kameswaran 
et al., 2014 
 
 
 
CG4Assay1R ATCAAAACAACTCAAATCCTTTATAAC 
CG4Assay1seq CCTTTATAACAAATTAAAATATATC 
IG-DMR 
Assay2 
CG4Assay2F GTTTTATTATTGAATTGGGTTTGTTAGTA 
CG4Assay2R 5'Biotin- ATCAAAACAACTCAAATCCTTTATAAC 
CG4Assay2seq AATTGGGTTTGTTAGTAG 
MEG3-
DMR 
Assay1 
CG7Assay1F 5'Biotin- ATTATAGGGTGTTGGTTATGG 
CG7Assay1R CCCCAAATTCTATAACAAATTACTCT 
CG7Assay1seq CAACAAAAAAAAAAAAAAAAAATTC 
MEG3-
DMR 
Assay2 
CG7Assay2F 5'Biotin- TTAGATTGTAGTAAAGAAGGGAGGAAAAAA 
CG7Assay2R CCCCCACACATTATACCTAAATTC 
CG7Assay2seq ATTATACCTAAATTCACCCT 
SNRPN 
ICR 
 
SNRPN F 5'Biotin- AGGGAGTTGGGATTTTTGTATT 
White et al., 
2006  
SNRPN R CCCCAAACTATCTCTTAAAAAAAAC 
SNRPN seq1 ACACAACTAACCTTACCC 
SNRPN seq2 CCAACCTACCTCTAC 
Bisulfite sequencing  
hIC1 
CTS3 
 
CTS3F GGGAGATGAGATATTTTGGTGATAATG 
Beygo et al., 
2013 CTS3R CCCCATCCAAAAAAAACTTAAAC 
COBRA 
IC1 
(CTS3) 
 
CTS3F GGGAGATGAGATATTTTGGTGATAATG 
Beygo et al., 
2013 CTS3R CCCCATCCAAAAAAAACTTAAAC 
IC2 
 
 
IC2F GGTAGGATTTTGTTGAGGAGTTTT 
This study 
 
 
IC2R CACACCCAACCAATACCTCATA 
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Table 5.7 qRT-PCR primers for iPSCs and EBs 
 
Gene Forward Reverse Reference 
Differentiation markers for embryonic body 
AFP AGCTTGGTGGTGGATGAAAC CCCTCTTCAGCAAAGCAGAC 
Teo et al., 
2011 
GATA4 TCCCTCTTCCCTCCTCAAAT TCAGCGTGTAAAGGCATCTG 
Park et al., 
2008 
HAND1 TGCCTGAGAAAGAGAACCAG ATGGCAGGATGAACAAACAC 
This study, 
designed 
using 
Pubmed 
primer 
blast 
RUNX2 CACTCACTACCACACCTACC GTCGCCAAACAGATTCATCC 
Cai et al., 
2006 
NCAM1 ATGGAAACTCTATTAAAGTGAACCTG TAGACCTCATACTCAGCATTCCAGT 
Park et al., 
2008 
FGF5 CGCTATGTCTTCCTCTTCTGC CAAAACACTTAACATATTGGCTTCG 
Higgins et 
al., 2014 
Pluripotency markers 
OCT4 CGACCATCTGCCGCTTTG GCCGCAGCTTACACATGTTCT Anokye-
Danso et 
al., 2011 
SOX2 ACAGCAAATGACAGCTGCAAA TCGGCATCGCGGTTTTT 
NANOG CCAAAGGCAAACAACCCACTT CGGGACCTTGTCTTCCTTTTT 
DNMT3B GGAAATTAGAATCAAGGAAATACGA AATTTGTCTTGAGGCGCTTG This study, 
designed 
using 
Roche 
Universal 
ProbeLibra
ry program 
GDF3 CGCTTTCTCCCAGACCAA GGCAGACAGGTTAAAGTAGAGGAG 
TERT GCCTTCAAGAGCCACGTC CCACGAACTGTCGCATGT 
LIN28A AAGCGCAGATCAAAAGGAGA CTGATGCTCTGGCAGAAGTG 
H19, IGF2, GAPDH, and PPIG 
H19 GCAAGAAGCGGGTCTGTTT GCTGGGTAGCACCATTTCTT 
Hiura et 
al., 2013 
IGF2 ACACCCTCCAGTTCGTCTGT GAAACAGCACTCCTCAACGA 
GAPDH GTCGTGGAGTCCACTGGCGTC TCATGAGTCCTTCCACGATAC 
PPIG 
GAAGAGTGCGATCAAGAACCCATGAC GTCTCTCCTCCTTCTCCTCCTATCTTT 
Cheng et 
al., 2012 
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